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Summary
Janus kinases Jakl and Tyk2 play an important role in urokinase-type plasminogen 
activator (uPA)-dependent intracellular signaling. Recent findings demonstrate that both 
kinases are associated with the uPA receptor (uPAR) and mediate uPA-induced activa-
tion of signal transducers and activators of transcription (Statl, Stat2, and Stat4) in hu-
man vascular smooth muscle cells (VSMC). Janus kinases are not only required for Stat 
activation but may also interfere with other intracellular signaling pathways. In the present 
study, one novel molecular mechanism for a cross-talk of the Janus kinase Tyk2-directed 
signaling cascades was elucidated. It was demonstrated that in VSMC, Tyk2 interacts with 
a downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3-K) and that 
this interaction is required for the uPA-related cell migration.
With the help of the developed adenoviral gene transfer it was demonstrated that the 
uPA-induced PI3-K activation was abolished in VSMC expressing the dominant negative 
form of Tyk2. The interactions of PI3-K and Tyk2 were studied using immunoprecipitation 
and pull-down assays. The regulatory subunit p85 of PI3-K co-immunoprecipitated with 
Tyk2 but not with Jakl, Jak2, or Jak3, and uPA stimulation increased the PI3-K activity in 
Tyk2 immunoprecipitates. Tyk2 directly bound to either of the two Src homology 2 (SH2) 
p85 domains in a uPA-dependent fashion.
The participation of Tyk2 and PI3-K in uPA-related cell migration was studied using 
chemotaxis assay in modified Boyden chamber and by means of time-lapse videomi-
croscopy. These experiments demonstrate that the Tyk2-mediated PI3-K activation in 
response to uPA was required for VSMC migration. Thus, two unrelated structurally dis-
tinct specific inhibitors of PI3-K, wortmannin and LY294002, prevented VSMC migration 
induced by uPA. No migratory effect of uPA was observed in VSMC expressing the domi-
nant negative form of Tyk2.
With the help of immunocytochemistry combined with time lapse vidoemicroscopy 
in wounding model, cytoskeletal reorganization in migrating VSMC was revealed that 
required association of Tyk2 and PI3-K.  Formation of actin-rich lamellipodial extentions 
at the leading edge of migrating cells and abundant stress fibers in response to uPA was 
abrogated in VSMC expressing a Tyk2 mutant form.  Similar effects were induced by cell 
treatment with the PI3-K inhibitors, wortmannin and LY294002.
These results underscore the versatile function of Tyk2 in uPA-related intracellular sig-
naling and indicate that PI3-K plays a selective role in the regulation of VSMC migration.
The functional role of endogenous uPA for VSMC migration was studied in coculture 
model, as far as uPA expressed by monocytes is a potent chemotactic factor for VSMC 
and might serve for the acceleration of vascular remodeling. This study demonstrates that 
coculture of human VSMC with freshly isolated peripheral blood-derived human mono-
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cytes results in significant VSMC migration that increases during the coculture period. 
Accordingly, VSMC adhesion was inhibited with similar kinetics, whereas VSMC prolif-
eration was arrested. The increase of VSMC migration in coculture was equivalent to the 
uPA-induced migration of monocultured VSMC and was blocked by addition into coculture 
of soluble uPAR (suPAR) that served as a competitor for the uPA binding.
These results lead to proposal that the upregulated uPA production at the place of 
vascular injury acts most likely as an endogenous activator of VSMC migration contribut-
ing to the remodeling of vessel wall. The underlying molecular mechanism involves activa-
tion and association of Tyk2 and PI3-K leading in turn to cytoskeletal rearrangement and 
increase in cell motility.
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Zusammenfassung
Die Janus Kinasen Jak1 und Tyk2 spielen eine wichtige Rolle in der  urokinase-type 
plasminogen activator (uPA)-abhängigen intrazellulären Kommunikation. Neueste Befunde 
demonstrieren, das beide Kinasen mit dem uPA-Rezeptor assoziert sind und die uPA-in-
duzierte Aktivierung von Proteinen der „signal transducers and activators of transcrip-
tion“-Familie (Stat1, Stat2 und Stat4) in humanen glatten Muskelzellen (VSCM) vermitteln. 
Janus Kinasen sind nicht nur für die Stat-Aktivierung notwendig, sondern können auch 
mit anderen intrazellulären Signalwegen interagieren. In der vorliegenden Arbeit wurde 
ein neuartiger molekularer Mechanismus für eine Querverbindung der Janus-Kinase Tyk2 
beleuchtet. Es konnte gezeigt werden, das Tyk2 mit einem Phostphatidylinositol-3-Kinase 
(PI3-K) beinhaltenden Signalweg interagiert und das diese Interaktion in VSCM für mit 
uPA zusammenhängende Zellmigration notwendig ist.
Mit Hilfe des entwickelten adenoviralen Gentransfers konnte gezeigt werden, dass 
die uPA-induzierte PI3-K Aktivierung durch Expression der dominant negativen Form von 
Tyk2 in VSCM aufgehoben werden konnte. Die Interaktion von PI3-K und TYk2 wurde 
sowohl durch Immunpräzipitation als auch durch Pull-Down Assays überprüft. Die regu-
latorische Untereinheit p85 der PI3-K konnte mit Tyk2 co-immunopräzipitiert werden, je-
doch nicht mit Jak1, Jak2 oder Jak3. Weiterhin wurde die Aktivität der co-immunopräzipi-
tierten PI3-K durch uPA erhöht. Tyk2 wurde uPA-abängig an beiden Src homology2 (SH2) 
Domänen der p85 Untereinheit gebunden.
 Die Beteiligung von Tyk2 und PI3-K an der mit uPA zusammenhängenden 
Zellmigration wurde in einem Chemotaxis Assay in einer modifizierten Boyden-Kammer 
und durch Zeitraffer Videomikroskopie untersucht. Diese Versuche zeigten, dass Tyk2-
vermittelte PI3-K Aktivierung nach uPA Stimulation für die Migration von VSMC notwendig 
ist. Die uPA induzierte Migration von VSCM wurde von zwei nicht verwandten, strukturell 
unterschiedlichen spezifischen Inhibitoren von PI3-K, Wortmannin und LY294002, ver-
hindert. Bei Expression der dominant negativen Form von Tyk2 wurde kein migratorischer 
Effekt der uPA Behandlung gesehen.
Durch Immunocytochemischen Methoden verbunden mit Zeitraffer Videomikroskopie 
wurde in einem Verwundungsmodell belegt, das die zytoskelletale Reorganisation in 
migrierenden VSCM eine Assoziation von Zyk2 und PI3-K bedarf. Die Bildung von Actin-
reichen, lamellipodalen Ausstülpungen am ventralen Ende der Zelle und zahlreichen 
Stressfasern als Antwort auf uPA-Stimulation wurde durch die Expression einer Tyk2 
Mutante aufgehoben. Ähnliche Effekte wurden durch die Behandlung von VSCM mit den 
PI3-K Inhibitoren Wortmannin und LY294002 erzielt.
Diese Resultate unterstreichen die vielseitige Funktion von Tyk2 in der uPA-ver-
wandten, intrazellulären Signaltransduktion und zeigen, das PI3-K eine Rolle in der 
VRegulation der Migration von VSCM spielt.
Die funktionelle Rolle von endogenem uPA für VSCM Migration wurde in einem 
Co-Kultur Modell untersucht. Hier wurde überprüft, in wie weit von Monozyten exprimi-
ertes uPA, in der Co-Kultur ein potenter chemotaxischer Faktor für VSMC sein und eine 
Beschleunigung des Gefäß-Remodeling herbeiführen könnte. Diese Untersuchung 
zeigte, dass Co-Kultur von humanen VSMC mit frisch isolierten humanen Monozyten 
aus peripherem Blut zu einer signifikanten Erhöhung der Migration von VSMC während 
der Co-Kultur Periode führte. Folglich wurde die Adhäsion von VSMC mit einer ähnlichen 
Kinetik inhibiert, während die Proliferation von VSCM gestoppt wurde. Die Zunahme der 
Migration von VSMC in Co-Kultur war äquivalent zur Induktion durch uPA von VSMC 
Migration in Monokultur und wurde durch Zugabe von löslichem uPAR in die Kultur ge-
blockt, das um die uPA-Bindung kompetierte?
Diese Resultate führen zu der Annahme, dass die bei einer Gefäßverletzung ho-
chregulierte uPA Produktion sehr wahrscheinlich als ein endogener Aktivator der 
Migration von VSMC beiträgt, die zum Remodeling des Gefäßwand beiträgt. Die un-
terliegenden molekularen Mechanismen schließen die Aktivierung und Assoziation von 
Tyk2 und PI3-K ein, die wiederum zu zytoskelletaler Reorganisation und zunehmender 
Zellbeweglichkeit führen.
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% (v/v) percent by volume
% (w/v) percent by weight
A: Ampere (Unit)
A260: Absorbance at 260 nm
A280: Absorbance at 280 nm
Ab: Antibody
Amp: Ampicillin
APS: Ammonium persulphate
ATCC: American-Type Culture Collection (Rockville, US)
ATP: Adenosine Triphosphate; Adenosine-5 -Triphosphate
bp: base pair
BSA: Bovine Serum Albumin
C: Degree Centigrade
CASMC: Coronary Artery Smooth Muscle Cell
cDNA: Complementary Deoxyribonucleic Acid
Ci: Curie (Unit)
cpm: Counts per Minute
DMEM: Dulbecco’s Modified Eagle Medium
DMPC: Dimethylpyrocarbonate
DMSO: Dimethyl sulfoxide
DNA: Deoxyribonucleic Acid
DNase: Deoxyribonuclease
dNTP: 2’-deoxynucleotide-5’- triphosphate
DTT: Dithiothreitol
ECL: Enhanced chemiluminescence
EDTA: Ethylenediaminetetraacetic Acid
ELISA: Enzyme-Linked Immunosorbent Assay
FACS: Fluorescence-Activated Cell Sorter
g: gram(me)
GPI: Glycosylphosphatidylinositol anchor
GTP: Guanosine Triphosphate; Guanosine 5 -Triphosphate
h: hour
HEPES : N-(2-Hydroxylethyl)piperazine-N -(2-Ethanesulfonic Acid)
IgG:  Immunoglobulin G
k: kilo=103
kb: kilobase
l: liter
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LB: Luria Bertani
m: milli=10-3
M: Molar
min: minute
moi: multiplicity of infection
MOPS: 3-(N-Morpholino)propanesulfonic Acid
n: nano=10-9
p: pico=10-12
PAGE: Polyacrylamide Gel Electrophoresis
PBS: Phosphate-Buffered Saline
PCR: Polymerase Chain Reaction
pfu plaque forming units
PMSF: Phenylmethanesulfonyl Fluoride
PVDF: Polyvinylidene Fluoride
RNA: Ribonucleic Acid
RNase: Ribonuclease
rpm: revolutions per minute
RT: Room Temperature
RT: Reverse Transcription
scuPA: single chain uPA
SDS: Sodium Dodecyl Sulfate
sec: second
TAE: Tris Acetate EDTA
tcuPA: two chain uPA
TEMED: N,N,N’,N’-Tetramethylethylenediamine
TRIS: Tris(hydroxymethyl)aminomethane
Tris: Tris (hydroxymethyl)-aminomethane
uPA: Urokinase
uPAR: Urokinase  Receptor
V: Volt (Unit)
x g: g force
µ micro=10-6
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Amino Acid Three-Letter Abbreviation
One-Letter 
Symbol Amino Acid
Three-Letter 
Abbreviation
One-Letter 
Symbol
Alanine Ala A Isoleucine Ile I
Arginine Arg R Leucine Leu L
Asparagine Asn N Lysine Lys K
Aspartic acid Asp D Methionine Met M
Asparagine or 
aspartic acid Asx B Phenylalanine Phe F
Cysteine Cys C Proline Pro P
Glutamine Gln Q Serine Ser S
Glutamic Acid Glu E Threonine Thr T
Glutamine or 
glutamic acid Glx Z Tryptophan Trp W
Glycine Gly G Tyrosine Tyr Y
Histidine His H Valine Val V
Abbreviations for Amino Acids
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1Introduction
1 Introduction
1.1 Atherosclerosis and it’s Progression
Atherosclerosis, a disease of the large arteries, is the primary cause of cardiovascular 
diseases and stroke. The key event of atherosclerosis is vascular remodeling resulting in 
the development of neointimal fibrocellular lesions, which can severely restrict blood flow 
and cause stenosis. Vascular reconstruction, such as coronary angioplasty, endatherec-
tomy, bypass surgery and vascular stents is often successful initially. However, periodic 
stenosis with an extracellular matrix (EM) ranging from loose collagen fibrils and proteo-
glycans to a dense collagen scar with few inflammatory cells remains one of the major 
limitations of these procedures. Restenosis occurs in 30-50% of patients within 6 months 
after the operation (Forrester et al., 1991; Ellis et al., 1998).
Pathological studies have revealed a series of changes in the blood vessels during 
atherogenesis. The hypothesis that an injury to the endothelium may have a key role 
in the atherosclerotic process was proposed in 1973 (Ross and Glomset, 1973). It was 
shown that a primary initiating event in this pathophysiological process is the accumula-
tion of the low-density lipoprotein (LDL) in the subendothelial matrix. Accumulation is in-
creased when the level of circulating LDL is raised. LDL diffuses through endothelial cell 
junctions and its retention in the vessel wall involves interaction between the LDL compo-
nent apolipoprotein B (apoB) and matrix proteoglycans (Boren et al., 1998). In addition to 
LDL, other apoB-containing lipoproteins can accumulate in the intima and promote ath-
erosclerosis. It has been shown that trapped LDL undergoes aggregation and oxidation, 
and that these modifications contribute to inflammation and foam-cell formation. Oxidized 
LDL (oxLDL) may not only directly injure the endothelium but also stimulate endothelial 
cells to produce adhesion molecules, chemotactic proteins such as monocyte chemotac-
tic protein-1 (MCP-1) and growth factors such as macrophage colony-stimulating factor 
(M-CSF), resulting in the recruitment of monocytes and T lymphocytes to the vessel wall 
(Fig. 1). It has been reported that adhesion molecules such as ICAM-1, P-selectin, E-
selectin (Dong et al., 1998; Collins et al., 2000), VCAM-1 and VLA-4 (Shih et al., 1998) 
are important for the adhesion of leukocytes and monocytes to endothelium. These cells 
then migrate through the endothelium and localize subendothelially. The cytokine M-CSF 
(Smith et al., 1995) stimulates the proliferation and differentiation of macrophages, and 
in cooperation with tumor necrosis factor-α (TNFα) and interferon-γ (IFN-γ) (Tontonoz et 
al., 1998) it increases the expression of scavenger receptors. Macrophages internalize 
oxLDL through both scavenger receptors (Goldstein et al., 1979) and a postulated oxLDL 
receptor. Intracellular accumulation of lipids leads to the formation of foam cells. Such fatty 
streaks are the early lesions of atherosclerosis. In such lesions, activated macrophages, 
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Fig.  1 The development of atherosclerosis process (Ross, 1993).
The dysfunction of endothelial cells is an important step in the beginning of atherosclerotic process. The 
adherence of monocytes, macrophages, T-lymphocytes to the injured endothelium is increased. Adhered cells 
migrate into the subendothelial space. The macrophages accumulate lipids and become foam cells. T cells 
and foam cells form a fatty streak lesion. The numerous growth-regulatory molecules and cytokines produced 
by the cells in fatty streaks, lead to proliferation and migration of smooth muscle cells from the media into the 
subendothelial space. The lesion is progressing to a fibrofatty lesion and then to a fibrous plaque. Secreted 
fibrous components result in increased lesion size. Activated macrophages, smooth muscle cells, T-cells 
and endothelium proceed with releasing regulatory molecules. This leads to advanced lesions, platelet 
adherence and to a thrombus formation. The advanced lesion is characterized by lipid-rich necrotic debris 
and smooth muscle cells, which are also, form a fibrous cap. The platelets release different regulatory 
molecules, which enhance the pathological process. In this figure: VSMC, blue; endothelium, red; macrophage, 
violet; platelet, green, T cells, pink.
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T-cells, and endothelium continue to release numerous growth-regulatory molecules and 
cytokines that contribute to the progression of atherosclerosis. MCP-1 (Yla-Herttuala et 
al., 1991) oxLDL (Quinn et al., 1988) and TGFβ (Sporn et al., 1987) can induce mac-
rophage chemotaxis, whereas growth factors such as PDGF (Hart et al., 1988) bFGF 
(Folkman et al., 1988) IGF-1 (Banskota et al., 1989), IL-1 (Raines et al., 1989) TNFα (Old, 
1985) and also TGFβ (Moses et al., 1990) can induce VSMC proliferation. None of these 
factors work alone in the process of atherogenesis. Through a network of cellular interac-
tions, the release of one factor can stimulate the expression of another one.
As a result, the formed fatty streak can progress to fibrofatty lesions and then to a 
fibrous plaque. A fibrous plaque is caracterized by a subendothelial mass of extracellular 
lipids and by the accumulation of VSMC and VSMC-derived extracellular matrix. It is im-
portant to note that accumulation of intimal VSMC is fundamental to the entire process. 
The endothelial injury increases the concentration of plasma proteins in the subendo-
thelial space. VSMC migrate into the intima. VSMC migrate from the media layer into the 
subendothelial space and change their function from contractile to secretory. Connective 
tissue matrix components are the secretory products of VSMC. With the secretion of fi-
brous components by VSMC fibrous plaques develop and increase in size, resulting in the 
progressive narrowing of the vessel lumen. Thus, migrating VSMC and their products are 
some of the central players in the development of vasculopathy. VSMC migrated into the 
intima are able to further proliferate and to accumulate modified lipoproteins, thus contrib-
uting to foam cells formation (Hayashi et al., 1992). With time, foam cells undergo necro-
sis that leads to the formation of a necrotic core and accumulation of extracellular lipids. 
Production of matrix metalloproteinases by macrophages contributes to the weakening 
of the fibrous plaque (Galis et al., 1994). Plaque rupture exposes lipids and tissue factors 
to blood components, initiating coagulation, platelet adherence, and the formation of a 
thrombus. Advanced atherosclerotic lesions can lead to ischemic symptoms, myocardial 
infarction and stroke (Lee and Libby, 1997).
It has been shown that the severity of vascular damage is dependent on the fibrinolyt-
ic system (Carmeliet and Collen, 1997; Carmeliet et al., 1997a; Carmeliet et al., 1997b), 
which plays a prominent role in the progression of atherosclerotic lesions, most likely by 
affecting VSMC proliferation, migration and adhesion (Waltz et al., 1997; Blasi, 1999).
1.2 Functions of uPA and uPAR in the Plasminogen Activation System
Extracellular proteolysis plays a key role in blood coagulation, fibrinolysis, vascular 
remodeling, angiogenesis, wound healing, and growth and metastasizing of malignant 
tumors. These proteases are located on the cell surface due to specific interaction with 
membrane-bound proteins and are responsible for degradation of the pericellular matrix 
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components and for destruction of cell-cell contacts. Thus, these proteases remove fibrin 
deposits and also provide the cell invasion/migration within tissues.
The urokinase-type and tissue-type plasminogen activators (uPA, or urokinase, and 
tPA, respectively) are important components of the extracellular protease system be-
cause they specifically convert plasminogen into plasmin. Plasmin is a serine protease 
with wide substrate specificity. Upon the generation of intravascular thrombi mainly consti-
tuted of polymeric fibrin, the system of plasminogen activators is triggered to recover the 
blood flow, and the plasmin directly degrades fibrin that leads to the thrombus dissolving. 
The plasminogen activators are believed to be key components of the fibrinolysis system. 
On the cell surface plasmin activates a number of metalloproteinases that degrade the 
extracellular matrix proteins and the components of basal membrane, such as collagen, 
fibronectin, and laminin. The combined effects of the plasminogen activators, plasmin, 
and metalloproteinases on the plasma membrane promote a vector cell movement due 
to destruction of the cell—cell contacts and the matrix and also due to the activation or 
releasing of latent or matrix-bound growth factors possessing chemotactic properties.
The tissue-type plasminogen activator is mainly involved in fibrinolysis, whereas the 
urokinase-type plasminogen activator, in addition to the fibrinolytic function, plays the 
most important role in cell migration and tissue remodeling.
On the cell surface urokinase binds to the high affinity receptor (uPAR), which is lo-
cated on the leading edge of the migrating cells. The binding of urokinase to the receptor 
provides a strictly local proteolysis of the extracellular matrix proteins in the direction of 
the cell movement. Moreover, the urokinase—receptor complex activates the intracellular 
signaling and thus regulates the cell adhesion, migration, and proliferation. Furthermore, 
the urokinase receptor and its specific inhibitor (PAI-1) can interact with adhesion recep-
tors, extracellular matrix proteins, and also with proteins which mediate the activation 
of intracellular signaling. These findings allowed considering the system of plasminogen 
activators as a separate group of regulators of cell movement and communication, which 
provide proteolytic and “signaling” functions.
1.3  The Structure and Processing of Urokinase
Urokinase is synthesized by vascular endothelial and smooth muscle cells (SMC), by 
epithelial cells, fibroblasts, monocytes/macrophages, and also by cells of malignant tu-
mors of different origin (Gelehrter et al., 1983; Golder and Stephens, 1983; Angles-Cano 
et al., 1985; Clowes et al., 1990). Cells secrete this protein as a single-chain polypeptide 
with molecular weight of 54 kD that consists of 411 amino acid residues. The urokinase 
structure is subdivided into three domains: the N-terminal domain homologous to the 
epidermal growth factor (amino acids 9-45), the kringle domain (amino acids 46-143), 
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and the C-terminal catalytic domain (amino acids 144-411) (Fig. 2). The “growth factor-
like domain” (GFD) is responsible for the interaction of urokinase with the uPAR receptor 
(Appella et al., 1987). The protease domain of urokinase includes the active site of the 
enzyme represented by a specific for serine proteases amino acid triad His204, Asp255, 
and Ser356. The kringle domain of urokinase contains a sequence that interacts with the 
specific inhibitor PAI-1 (Mimuro et al., 1992). It has also been found that urokinase binds 
to heparin through the kringle domain, but the functional significance of this interaction is 
yet unclear (Stephens et al., 1992). The interaction of urokinase with this receptor results 
in the migration of SMC, (Pollanen et al., 1988), fibroblasts and of a number of other cells 
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Fig. 2     Aminoacid structure of uPA.
The arrows denote the sites of pro-uPA plasminolysis. The cleavage of the Lys158-
lle159 peptide bond of pro-uPA converts a proteolytically inactive single-chain uPA into 
the double chain proteolytically active uPA. Active uPA consists of two polypeptide chains, 
which are connected to each other through a disulfide brige (Cys148-Cys279). The A-
chain includes the epidermal growth factor like domain (EOF, aminoacids 1-49, red) and 
the kringle domain (KD, aminoacids 50-131, green) whereas the B-chain includes the 
serine protease domain (SPD, amonoacids 159-411, blue). The aminoacid triad Ser356-
His204-Asp255 is responsible for the proteolytic activity of uPA. Splitting of the peptide 
bond not only in Lys158-lle159 but also in Lys135-Lys136 results in the ATF fragment of 
uPA.
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(Clowes et al., 1990).
The single-chain urokinase has no peptidase activity to synthetic substrates. 
Therefore, this urokinase form was for a long time considered as the enzyme precursor, 
or prourokinase (Wun et al., 1982). However, prourokinase can convert plasminogen into 
plasmin. Plasmin, in its turn, activates urokinase because it cleaves the Lys158—Ile159 
peptide bond and converts the single-chain urokinase into the two-chain form (Fig. 2). The 
two-chain urokinase reveals protease activity with respect to both synthetic substrates 
and plasminogen, and the rate of plasminogen cleavage by the two-chain urokinase is 
more than 200-fold higher than the rate of cleavage by the single-chain form (Lijnen et al., 
1990). Other extracellular proteases, such as kallikrein, blood coagulation factor Xlla, and 
cathepsin B, also cleave the Lys158—Ile159 bond of urokinase. The polypeptide chains 
A and B (light and heavy chains, respectively) are connected by the Cys148-Cys279 di-
sulfide bond in case of the two-chain urokinase The A-chain includes the “growth” and the 
kringle domains, whereas the proteolytic domain is a part of the B-chain. Upon cleavage 
of the Lys158—Ile159 bond a newly generated amino terminal tail of the B-chain with Ile 
159 on the end is relocated into the region of the substrate-binding pocket of the protease. 
This is associated with the formation of anion pair between the NH2-group of the Ile 159 
and the side chain of Asp255. These conformational changes result in the opening of the 
substrate-binding pocket and, possibly, of the active site of the enzyme (Goldberg et al., 
1990).
A 32-kD urokinase was isolated from adenoma cell culture (Stump et al., 1986a). This 
low-molecular-weight form of the protein is a single-chain fragment of urokinase contain-
ing amino acids 144-411. The enzymatic properties of this fragment are virtually the same 
as the properties of the full-length urokinase. The low-molecular-weight two-chain uroki-
nase is generated after the cleavage of the Lys135—Lys136 bond by plasmin in the re-
gion between the kringle and protease domains, and its proteolytic activity is comparable 
to the activity of the full-length two-chain urokinase (Stump et al., 1986b). Because the 
urokinase cleavage in this region can separate the A- and B-chains, it is obvious that in 
addition to the low-molecular-weight urokinase an amino terminal fragment of the protein 
is generated (Kobayashi et al., 1985). Nevertheless, up to now the amino terminal frag-
ment is prepared by the cleavage of the full-length urokinase by protease V8. Thrombin 
hydrolyzes the Arg156—Phe157 peptide bond that results in formation of a two-chain uro-
kinase variant that is proteolytically inactive and fails to be activated by other proteases 
(Fig. 2). Such processing is a mechanism for inactivation of the enzyme (Ichinose et al., 
1986; Braat et al., 1999). However, the resulting inactive form probably has other func-
tions on the cell surface that are not associated with proteolysis.
Thus, a number of bonds in urokinase undergo proteolytic cleavage with formation of 
several variants of the protein on the cell surface (Fig. 2). The full-length, single-, and two-
chain forms of urokinase and its amino terminal fragment can bind to the uPAR receptor 
on the cell surface. 
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1.4  The Urokinase Receptor
The discovery of the urokinase receptor in 1985 (Bajpai and Baker, 1985; Stoppelli 
et al., 1985) opened a new dimension in the study of extracellular proteolysis and matrix 
degradation. The proteolytic cascade system of plasminogen activation had long been 
recognized as performing a central role in these processes (Andreasen et al., 1997). It 
was soon demonstrated that the novel receptor, uPAR, could localize uPA on a wide range 
of cell types (Nielsen et al., 1988) and further to specific compartments on the surface of 
the cells, typically at sites involved in focal cell-substratum and cell-cell contacts (Pollanen 
et al., 1988). It was realized that at these sites the bound ligand remained enzymatically 
active (Appella et al., 1987), and kinetic studies showed that the plasminogen activation 
cascade system became accelerated when the reactants were cell-bound (Ellis et al., 
1989; Stephens et al., 1989). These observations were highly relevant for the hypothesis 
that the uPA system does have an involvement in processes of pericellular tissue degra-
dation such as those occurring in cancer invasion. Subsequent work led to the elucidation 
of several aspects, of the processes in which uPAR is involved and even the identification 
of novel roles of the receptor system, in addition to those directly related to proteolysis.
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Fig. 3  Aminoacid structure of uPAR. 
The polypeptide chain  is composed of three domains (domain 1 (D1), blue; domain 2 (D2), green; 
domain 3 (D3) red) connected by two short linker regions. Four aminoacid bonds represent the protease 
sensitive part of linker region between domains 1 and 2. uPAR is linked to the membrane by a GPI anchor. 
The solid short black lines depict disulfide bonds, which are holding uPAR in a proper conformation. The 
symbol (S-S) indicates the number of disulfide bonds in each domain. Rhombi correspond to the potential 
glycosylation sites.
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The number of uPAR molecules per cell varies markedly, with values from a few thou-
sands to several hundred thousands being reported (Picone et al., 1989). Ligand binding 
is reversible with a Kd in the range of 0.1-1 nM and occurs with active uPA as well as the 
zymogen pro-uPA (Stoppelli et al., 1985; Vassalli et al., 1985). The interaction allows the 
proteolytic activation of the bound zymogen (Cubellis et al., 1986) at the very site where 
plasminogen activation also occurs. More recently, it has become clear that uPAR also 
binds to vitronectin in a manner that allows this ligand and uPA to be bound simultane-
ously (Wei et al., 1994)
The human (Behrendt et al., 1990) and murine (Solberg et al., 1992) uPARs have 
been purified and characterized and uPAR-encoding cDNAs from human (Roldan et al., 
1990), murine (Kristensen et al., 1991) , rat (Rabbani et al., 1994) and bovine (Reuning 
and Bang, 1992; Kratzschmar et al., 1993) cells have been cloned and sequenced. The 
human cDNA encodes a 335 amino acid residue polypeptide, including an NH2-terminal 
signal peptide of 22 residues and a COOH-terminal segment that is removed during pro-
cessing for glycolipid membrane anchorage. The mature receptor protein probably com-
prises 283 residues (Ploug et al., 1991; Moller et al., 1993).
The uPAR protein (Fig. 3) is composed of three extracellular domains (Behrendt et al., 
1991; Behrendt et al., 1996) with a low but distinct mutual sequence homology (Palfree, 
1991). The consensus sequence pattern characterizing the domains of uPAR is refound 
in a group of proteins currently referred to as the uPAR/Ly-6 protein family. In addition to 
uPAR and the murine Ly-6 differentiation antigens, this family comprises the complement 
component CD59 (membrane inhibitor of reactive lysis; MIRL), the murine thymocyte 
/ B-cell antigen ThB (with the homologous Ag E48 on human keratinocytes) and gene 
product of herpesvirus saimiri HVS-15 (Behrendt et al., 1991; Palfree, 1991; Ploug et 
al., 1995). uPAR, however, is the only family member identified so far which has more 
than one domain. The disulfide pairing pattern of the first domain of uPAR (Ploug et al., 
1993) and that of CD59 (Sugita et al., 1993) have been solved, and the patterns identified 
clearly confirm the relatedness of these proteins . 
uPAR is anchored in the plasma membrane through a glycosyl-phosphatidylinosityl 
(GPI) moiety (Ploug et al., 1991). The protein thus has no intracellular domain and no 
membrane-spanning peptide segment, a property central to any understanding of the 
membrane distribution and to the discussion of functions such as cellular signal trans-
duction. The GPI anchor is coupled covalently during a post-translational processing 
event in which the COOH-terminal part of the nascent polypeptide is removed and the 
GPI structure becomes attached to a novel COOH-terminus which, in the case of human 
uPAR, is most likely Gly233 as concluded from mutagenesis studies (Moller et al., 1993). 
The primary structure of the human uPAR contains five potential N-glycosylation sites 
(Roldan et al., 1990), of which four have been found to be utilized. Indeed uPAR is heavily 
9Introduction
glycosylated, giving rise to a pronounced molecular heterogeneity, and leading to a sub-
stantial shift in electrophoretic mobility upon enzymatic deglycosylation (Behrendt et al., 
1990). A number of molecular studies have been done using a genetically-engineered, 
water-soluble uPAR variant (amino acid residues 1-277) which is devoid of the GPI moi-
ety (Ronne et al., 1994). This protein has the same ligand-binding properties as wild-type 
uPAR (Ploug and Ellis, 1994), and in the following it is considered functionally equivalent 
at the molecular level to the GPI-containing uPAR.
1.5  uPAR-mediated Signaling in Regulation of the Actin Cytoskeleton 
and the Effects on Cell Motility
Several of the signaling pathways affected by uPAR-mediated signaling are known 
to be involved in the regulation of the actin cytoskeleton and of integrin activation in con-
nection with cell migration. In some cases these pathways have now been functionally 
connected to uPAR-mediated promotion of cell motility.
Most evidence stems from studies on uPA-mediated ERK activation in cell motility. A 
transient uPA-induced activation of ERK via a pathway requiring FAK, Src, She and sub-
sequent engagement of the classical, Grb2/Sos/Ras/Raf/MEK pathway has been linked 
to an increase in migration of MCF-7 breast cancer cells in assays where serum was used 
as a chemoattractant and VN as the haptotactic stimulus (Nguyen et al., 1998; Nguyen 
et al., 1999; Nguyen et al., 2000). FAK, Src, and She are all needed for uPA-induced 
ERK activation in these cells, though FAK and She have been reported to activate ERK 
through parallel independent pathways in other settings (Schlaepfer et al., 1998; Giancotti 
and Ruoslahti, 1999) ERK activation is also necessary for the chemotaxis of rat smooth 
muscle cells towards pro-uPA  (Degryse et al., 2001).
In MCF-7 cells, the ERK activation leads to phosphorylation and activation of myosin 
light chain kinase (MLCK) and an MLCK-dependent increase in chemo-and haptokinetic 
cell motility (Nguyen et al., 1999). MLCK phosphorylates myosin II regulatory light chain, 
leading to the assembly of actomyosin filaments and contraction in smooth muscle cells 
(Kamm and Stull, 2001).The induction of cell contractility induced by MLCK mediated ac-
tivation of the actin-myosin motor is thus one downstream event by which uPA ligation of 
uPAR could be connected to the cellular machinery mediating cell motility.
Additional pathways regulate both MEK/ERK-dependent and obviously MEK/ERK-
independent cell migration. Current evidence indicates that uPAR might also be involved 
in motility regulation through some of these. There is evidence that one such pathway 
involves activation of Rac, a member of the Rho-family of small GTPases (Hall, 1998). 
Like other Rho GTPase family members, Rac plays an important role in the regulation of 
the actin cytoskeleton. Constitutively active Rac induces lamellipodia and protrusion for-
10
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mation in various cell types through activation of downstream effectors (Bishop and Hall, 
2000)  and Rac activity is essential for cell migration (Nobes and Hall, 1999). Rac can be 
activated through a pathway where phosphorylation of the substrate domain of the scaf-
folding protein p130Cas creates a binding site for the SH2 domain of the adaptor protein 
Crk (O’Neill et al., 2000). The further coupling of another adaptor protein DOCK180 to 
this complex leads to activation of Rac through an unknown mechanism (Kiyokawa et al., 
1998). The functional consequences of this pathway has been demonstrated in COS-7 
cells where lamellipodia formation and increased cell motility are induced by p130Cas/Crk 
co-expression or insulin treatment in a manner dependent on p130Cas/Crk association 
and Rac activity (Klemke et al., 1998; Cheresh et al., 1999). Interestingly, some uPAR-
mediated effects seem to be mediated via a similar pathway dependent on p130Cas 
and Rac. Increased expression of human uPAR in murine Swiss 3T3 fibroblasts induces 
prominent protrusions/lamellipodia in a p130Cas and Rac-dependent manner (Kjoller and 
Hall, 2001). In addition uPAR expression also induces a 4-fold increase in the levels of 
active Rac and increases random cell motility in a Rac-dependent manner. These events 
seem to be initiated by uPAR binding to vitronectin (VN). As mentioned above it has also 
been reported that in rat SMC, soluble VN induces chemotaxis and increases the number 
of cells showing a motile morphology in a uPAR-dependent manner (Degryse et al., 2001). 
In contrast to the uPA/uPAR induced effects on cell motility descibed above, the VN-in-
duced and uPAR-mediated or uPAR-dependent responses are insensitive to the inhibition 
of MEK/ERK. It is thus an interesting possibility that uPA and VN ligation of uPAR could 
regulate cell motility through at least partially different signaling pathways. The available 
data suggest that uPA would then be primarily responsible for inducing signaling to MEK/ 
ERK while VN would induce signaling through p130Cas/ Crk/DOCK180/Rac. This is in 
agreement with the observation that increased uPAR expression per se in MCF-7 cells 
induces a 6-fold increase in cell migration onto VN independently of MEK/ERK activity, 
which can be further increased (2-fold) by addition of uPA in a MEK/ERK sensitive man-
ner (Nguyen et al., 1999).
The fact that uPA binding to uPAR leads to an increase in uPAR binding to VN (Waltz 
and Chapman, 1994; Kanse et al., 1996) adds an additional level of complexity to the pos-
sible cooperation between uPA- and VN-induced pathways (Hoyer-Hansen et al., 1997). 
uPA might induce signaling through one pathway by causing a conformational change 
of uPAR that leads to interaction with one transmembrane protein, while it simultane-
ously promotes uPAR association to VN, an interaction which could induce an additional 
pathway (a pathway leading to p130Cas dependent Rac activation) through a different 
transmembrane mediator.
The notion that uPA and VN would induce two separate pathways is, however, un-
doubtedly an oversimplification as there is extensive cross-talk between the suggested 
11
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pathways. For example FAK and Src has been implicated not only in ERK activation but 
also in p130Cas activation (Vuori et al., 1996), and Rac has been reported to mediate 
cytoskeletal changes downstream of Ras (Ridley and Hall, 1992) results that are not im-
mediately consistent with the model. The regulation of cell migration through separate si-
galing pathways involving MEK/ERK and p130Cas, respectively, have however previously 
been suggested from a number of studies (Anand-Apte and Zetter, 1997; Cheresh et al., 
1999; Gu et al., 1999) using different migration stimuli.
Signaling via a heterotrimeric Gi protein has also been implicated in cell motility and 
concomitant morphology changes induced by ATF or su-PAR-D2D3 (Resnati et al., 1996; 
Fazioli et al., 1997; Blasi, 1999; Degryse et al., 1999; Degryse et al., 2001). The signaling 
pathways downstream of Gi have in this case been proposed to involve one or more kinas-
es of the Src-family due to the need for p56/59 Hck activation in monocytic cells (Fazioli et 
al., 1997; Chiaradonna et al., 1999) and the inhibition of chemotaxis and/or cytoskeletal 
changes by herbimycin A in RSMC (Degryse et al., 1999). Also Src-deficient fibroblasts 
do not respond chemotactically to uPA (Fazioli et al., 1997; Degryse et al., 1999). Both Gi 
and Src-type kinases have previously been found to have roles in chemotaxis and/or cell 
motility control. Gi thus has a well-established role in chemotaxis (Mellado et al., 2001). 
This appears to be independent of Gαi but instead involves the released Gβγ subunit com-
plex after activation of the heterotrimeric Gi (Neptune et al., 1999). A reconstruction of the 
events after chemoattractant-induced Gi activation by transfection of COS-7 cells sug-
gested that the Gβγ complex can induce cytoskeletal reorganization via a pathway lead-
ing to Rac activation through the γ isoform of PI3-K and the guanine nucleotide exchange 
factor Vav (Ma et al., 1998). This is thus one plausible way in which Gi could be involved 
in mediating uPA-induced changes in cell morphology and motility. PI3-K inhibitors have 
at least a partially inhibitory effect on ATF/uPA induced cell migration and chemotaxis 
(Degryse et al., 2001).
The function for Src in cell motility is believed to involve a role in focal adhesion turn-
over (Fincham and Frame, 1998), and Src-deficient fibroblasts spread and migrate less 
well than wild-type cells (Hall et al., 1996), so it is perhaps not surprising that uPA is not 
able to induce chemotaxis in Src-deficient cells (Fazioli et al., 1997). The evidence for ac-
tivation of Src-like kinases in response to uPA/uPAR induced signaling is, however, quite 
sparse. Only p56/p59Hck, which is primarily expressed in hematopoietic cells (Martin, 
2001) has been reported to be activated upon uPA binding. In hck-/-, fgr-/- macrophages, 
cell motility is impaired consistent with a role of Hck in uPA-induced motility in monocytes 
(Suen et al., 1999). Src is also implicated in the activation/regulation of other key players 
in motility regulation such as FAK, ERK and p130Cas (O’Neill et al., 2000; Martin, 2001), 
but it is not yet clear whether Src-type kinases are generally involved in uPA-induced sig-
naling to control cell motility in non-hematopoietic cells.
12
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Finally, several lines of research suggest that also one or more isoforms of PKC may 
have a role in uPAR-mediated regulation of cell motility. In a number of different cell types 
the induction of chemotaxis upon uPA or ATF treatment coincides with de novo forma-
tion of the PKC activator diacylglycerol (Del Rosso et al., 1993; Anichini et al., 1994) and 
sometimes translocation of PKC activity to the membrane  (Fibbi et al., 1998). The involve-
ment of PKCs has also been suggested from at least a partial inhibition of uPA-induced 
phosphorylation of cytokeratin (Busso et al., 1994), changes in the actin cytoskeleton 
(Carriero et al., 1999) and chemotaxis (Anichini et al., 1994; Degryse et al., 2001) after 
inhibiton of PKC. Several different PKC isoforms have been implicated in actin cytoskel-
eton regulation (Keenan and Kelleher, 1998) and PKC activation may thus be yet another 
pathway by which uPAR might affect cell motility.
With our current knowledge, it appears that uPAR at least has the potential to mediate 
signaling through several pathways that involve control of cell motility in general and the 
connected events such as actin cytoskeleton reorganization and integrin function in par-
ticular. This could be due to both activation of several different trans-membrane adaptors 
or result from activation of one major signaling pathway resulting in the relay of changes 
through cross-talk within the intracellular signaling network.
1.6  Structure-Function Analysis of the Janus Kinases
Discovery of the Janus kinases (JAKs) occurred at a time when a variety of approach-
es were being tested in attempts to identify novel protein tyrosine kinases. The first JAK 
kinase, which was named TYK2 (tyrosine kinase 2), was obtained upon screening a T-cell 
library using low stringency hybridization techniques (Krolewski et al., 1990; Firmbach-
Kraft et al., 1990). The unique structure and function of TYK2 became obvious only after 
other members of the JAK family were identified and characterized. Polymerase chain re-
action (PCR) using degenerate oligonucleotides spanning the heavily conserved kinase 
domains of members of the Src family of protein tyrosine kinases resulted in identification 
of partial cDNA clones of JAK1 and JAK2 (Wilks, 1989). Full-length cDNA clones of JAK1 
and JAK2 were subsequently cloned using the partial cDNA fragments as probes (Wilks, 
1991; Harpur et al., 1992). Their discovery, along with several other members of the ty-
rosine kinase family resulted in the usage of the acronym JAK (Just Another Kinase). 
Subsequent sequencing studies revealed that the JAK family of protein tyrosine kinases 
(PTKs) differs markedly from other classes of PTKs by the presence of an additional ki-
nase domain. To denote this unique structural feature, these kinases were renamed as 
‘Janus kinases’ in reference to an ancient two-faced Roman God of gates and doorways 
(Darnell, 1998; Darnell et al., 1994; Ihle et al., 1995, 1997; Pellegrini and Dusanter-Fourt, 
1997; Schindler and Darnell, 1995; Heim, 1999; Leonard and O’Shea, 1998; Schindler, 
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1999; Leonard and Lin, 2000; Ward et al., 2000).
Expression studies indicated that JAK1, JAK2 and TYK2 are ubiquitously expressed 
and are encoded by transcripts of 5.4 kb (JAK1), two transcripts of 5.3 and 5.0 kb (JAK2), 
and a 4.4 kb transcript (TYK2), respectively. Several independent groups identified and 
cloned a fourth member of the JAK family (Johnston et al., 1994; Rane et al., 1994; 
Kawamura et al., 1994; Takahashi and Shirasawa, 1994; Witthuhn et al., 1994). JAK3 is 
encoded by a 4.2 kb transcript that codes for a 120 kD protein that is expressed predomi-
nantly in cells of hematopoietic origin. Recently, reports describing JAK3 expression in 
normal and transformed human cell lines of various origins have been published (Lai et 
al., 1995; Verbsky et al, 1996).
The unique structure of the JAK kinases clearly distinguishes them from other mem-
bers of the protein tyrosine kinase family (Fig. 3). The most intriguing feature of these 
proteins is the presence of two domains (JH1 and JH2), with extensive homology to the 
tyrosine kinase domains. A second interesting feature is the absence of any SH2 or SH3 
domains. Instead, these proteins encode a group of well-conserved domains termed as 
JAK homology (JH1-JH7) domains that follow a non-conserved amino terminus of about 
30-50 amino acids. Of the dual kinase domains identified only the JH1 domain appears to 
be functional. The JH2 domain, which harbors considerable homology to the tyrosine ki-
nase domains lacks certain critical amino acids required for a functional kinase and does 
not appear to be associated with a kinase activity. Both the tyrosine kinase domain (JH1) 
and the pseudo-kinase domain (JH2) are housed at the carboxy terminus of the protein 
(Fig. 3). The other conserved blocks of sequences (JH3-JH7) that are characteristic to 
members of the JAK family, comprise approximately 600 N-terminal amino-acids resi-
dues. The precise functions of the JH3-JH7 domains as well as the pseudokinase domain 
(JH2) are currently under investigation. The sequences of the JH3-JH7 domains bear no 
resemblance to any characterized protein motif. Considering the variety of interactions 
and functions performed by the JAK kinase family members it seems plausible that these 
domains facilitate some key functions like protein-protein interactions, recruitment of sub-
strates, etc.
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Fig. 4  JAK structure.
The JAKs share seven regions of high homology,JH1-JH7. JH1 encodes the kinase, JH2 represents a 
pseudokinase domain, which appears to regulate JH1 catalytic activity. JH3-JH7 is implicated in receptor 
association.
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1.7 Activation of Jak Kinases by Cytokines/Interferons and Growth 
Hormones
Janus kinases are generally believed to be present in unstimulated cells in an inactive 
form. Ligand-induced receptor oligomerization, such as cytokine interaction with its spe-
cific receptor, serves as a trigger to signal the recruitment of JAKs to close proximity of the 
receptors. Local aggregation of the JAK kinases and their subsequent activation by either 
auto or trans phosphorylation is an event which either involves other members of the JAK 
kinase family, Src family of kinases and/or receptor tyrosine kinases. The JAK kinases 
(either alone as monomers or as homo or heterodimers) have been implicated in signal 
transduction processes initiated by a variety of growth factors and cytokines. A number of 
studies show that JAK kinases are involved in signaling by interleukins such as IL-2, IL-4, 
IL-7, IL-9 and IL-15 (Witthuhn et al., 1994; Zeng et al., 1994; Johnston et al., 1994; Kirken 
et al., 1994; Yin et al., 1994). JAK2 is activated following erythropoietin stimulation of its 
receptor (Witthuhn et al., 1993) while JAK1 and JAK2 have been implicated in signaling 
by IL-3, GM-CSF and IL-5 (Silvennoinen et al., 1993a; Quelle et al., 1994; Lutticken et al., 
1994). Stimulation by the cytokines IL-6, CNTF, and LIF results in the activation of JAK1, 
JAK2 and TYK2 kinases (Stahl et al., 1994; Guschin et al., 1995). Also, JAK2 and TYK2 
are activated upon IL-12 stimulation and are proposed to play a critical role in IL-12 medi-
ated T-cell differentiation (Bacon et al., 1995). Similarly, JAK kinases have been shown 
to play a key role in the signal transduction pathways initiated in response to stimulation 
by growth hormone (Argetsinger et al., 1996), prolactin (Rui et al., 1994; Dusanter-Fourt 
et al., 1994) and G-CSF (Nicholson et al., 1995; Shimoda et al., 1997). The interferons 
also transduce their signals via the JAK kinases, JAK1, JAK2 and TYK2 (Velazquez et al., 
1995; Watling et al., 1993). JAK3 conveys signals transduced from IL-2, IL-4, IL-7, IL-15 
and IL-19. In summary it appears that specific JAK kinases, either alone or in combina-
tion with other JAK kinases, may be preferentially activated depending on the type of the 
receptor that is being activated.
1.8  STATs 
STATs are among the best characterized JAK substrates and activation of virtually 
all cytokine/interferon/growth hormone receptors lead to the activation of one or more 
STATs. For example, IL-3 activation of hematopoietic cells appears to lead to the activa-
tion of multiple STATs, which include STAT-1, STAT-3, STAT-5 and STAT-6 (Reddy et al., 
2000). The nature of STATs that are activated appear to be more dependent of the cell 
line that is used in the study, rather than the cytokine or the nature of JAK activated by 
cytokine/receptor interactions. This observation suggests that neither the cytokine recep-
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tors nor the JAKs by themselves dictate the nature of STATs that are activated by a given 
cytokine. It is also interesting to note that a C-terminal deletion mutant of IL-3 βc chain, 
termed βc541 was found to be deficient in its ability to activate STAT-5, while still being 
able to activate JAK2 (Burfoot et al., 1997). These observations also imply that while 
JAK2 activation is a critical step in IL3/IL5/ GMCSF mediated activation of their cognate 
receptors; it is by itself not adequate for STAT activation.
1.9  Cross-Talk among Jaks and Components of other Signaling 
Pathways
Signal transduction in response to a variety of ligands involves the activation of the 
Ras signaling pathway (Egan and Weinberg, 1993). In the Ras pathway, typified by signal 
transduction in response to Erythropoietin as well as IL-3, cytokine stimulation results in 
the recruitment and tyrosine phosphorylation of She. Following phosphorylation, Grb2 as-
sociates with She and with Sos. This results in an increase in GTP-bound Ras, activation 
of Raf-1, followed by activation of the mitogen-activated (MAP) kinases and induction of 
primary response genes such as c-myc, c-fos, etc. Recently, several studies have explored 
the interdependence between the JAK kinase signaling pathway and the Ras-linked to 
MAP kinases pathway as well as other key signaling molecules such as Vav, PI-3 kinase 
and the protein tyrosine phosphatases such as SH-PTP1. Evidence from these studies 
Fig. 5  The JAK-STAT signaling 
pathway.
Upon binding ligand, receptor-as-
sociated JAKs become activated and 
mediate phosphorylation of specific 
receptor tyrosine residues. This leads to 
the recruitment of specific STATs, which 
are then also tyrosine-phosphorylated. 
Activated STATs are released from 
the receptor, dimerize, translocate to 
the nucleus, and bind to members of 
the γ-activated site (GAS) family of 
enhancers.
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suggests that there may be interactions amongst the diverse components of the cells’ sig-
nal transduction repertoire. Also, data indicates that cells have equipped themselves with 
‘safety routes’ in the event of malfunction of a particular ‘primary’ signaling pathway. The 
availability of an optional signaling route, available via interactions with multiple signaling 
molecules, enable cells to survive the loss of the ‘primary’ signaling route. Thus, although 
the Ras and JAK kinase pathways mediate distinct signals it is becoming evident that 
there may be interdependence between the two pathways. Thus, phosphorylation of the 
receptors by JAK kinases creates potential docking sites for adaptor molecules such as 
She, the p85 subunit of PI-3K, STAT proteins and other kinases such as Src-kinases 
which can associate with the phosphorylated receptors via their SH2 domains. Once re-
cruited to the receptor complex, the JAK kinases can phosphorylate multiple downstream 
signaling molecules to further propagate the Ras and JAK kinase pathways.
The abilities of various receptors to integrate activation of the JAK kinase pathway 
to elements of the Ras pathway have been extensively documented (Alam et al., 1995; 
Bates et al., 1996; Kumar et al., 1994). Carboxy terminal truncations in the IL-3 recep-
tor β-chain resulted in the loss of activation of the Ras pathway, although the ability to 
activate JAK2 and induce mitogenesis was retained providing evidence for the existence 
of alternate signaling pathways in cytokine signaling (Quelle et al., 1994). In a similar 
study, it was demonstrated that distinct regions of the G-CSF receptor are required for 
tyrosine phosphorylation of JAK2, STAT3 as well as p42, p44 MAP kinases. MAP kinase 
tyrosine phosphorylation correlated with both the proliferative response and JAK2 activa-
tion (Nicholson et al., 1995). Recently, (Mizuguchi et al., 2000) described the JAK kinase 
mediated activation of both the Ras and STAT pathways in cell proliferation. Conditional 
activation of JAK kinases confers IL-3 independence to BA/F3 cells that requires func-
tional Ras and STATS proteins. This observation indicates an obligatory role for the Ras 
and STAT proteins as targets of JAK activity. In agreement with the above studies, overex-
pression of Ras or STATS alone does not confer IL-3 independence whereas concomitant 
activation of Ras and STATS is sufficient to confer IL-3 independence. The same group 
also, elucidated the role of JAK kinase activity in Ras signaling using a TYK2 protein that 
was modified by the addition of a membrane localization sequence and a chemical di-
merizer (coumermycin)-dependent dimerization sequence (Mizuguchi and Hatakeyama, 
1998). The modified TYK2, upon activation by dimerization, conferred IL-3 independence 
to pro-B lymphoid cells that was abolished by expression of dominant negative Ras indi-
cating the mandatory role for Ras proteins as downstream targets of JAK kinase signals. 
Interferon stimulation led to activation of the Ras pathways that also depend on JAK 
kinase activities (Sakatsume et al., 1998; Stancato et al, 1997). Sakatsume et al. (1998) 
showed that activation of the Raf-1 protein by interferon gamma was Ras-independent 
but required the kinase activity of JAK1. Similarly, Stancato et al. (1997) reported that 
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activation of Raf-1 and the MAP kinase pathways, upon stimulation of cells with interferon 
beta and oncostatin M, required JAK1 kinase activity. The above studies, taken together 
indicate that JAK kinases target both the Ras and STAT pathways to exert their biological 
effects.
Activation of Ras and PBKinase as well as STAT proteins leads to increased induction 
of transcription factors such as c-jun. Also, c-jun levels are elevated in B-lymphoid cells 
exposed to ionizing radiation (IR). Goodman et al. recently demonstrated that the induc-
tion of c-jun in IR treated cells required the activation of JAK3 but was impervious to the 
activation status of the Btk, Syk and Lyn tyrosine kinases (Goodman et al., 1998).
Interaction of JAK2 with the SH2 domain of p95 Vav, a protein expressed in hema-
topoietic cells, was reported in cells stimulated with GM-CSF (Matsuguchi et al., 1995). 
Also, in IL-7 stimulated Tcells, members of the JAK family were shown to regulate the 
activity of PI-3 kinase. Coupling of the JAK signaling pathway and She phosphorylation 
was demonstrated in signal transduction events from c-Mpl, a member of the cytokine 
receptor family and the receptor for thrombopoietin (Gurney et al., 1995). Integration of 
the JAK and Ras pathways was evident in IL-6 induced signals in a B-cell line AF10 in 
which JAK1, p52Shc, Raf-1 and MEK-1 were activated (Kumar et al., 1994). Studies in-
volving signal transduction by growth hormone (GH) indicated that JAK2, Ras and Raf 
are required for activation of the MAP kinases (Winston and Hunter, 1995). Based on this 
study, it was suggested that JAK kinases might represent a common component during 
activation of the ERK2/ MAPK and STAT signaling pathways, which appeared to bifurcate 
upstream of Ras activation but converged with the phosphorylation of STATs by the ERK/ 
MAPK proteins. The role of JAK kinases in insulin signaling demonstrated that JAK1 and 
JAK2 constitutively associate with Grb2 via interactions with the SH3 domains of Grb2 
(Giorgetti-Peraldi et al., 1995). Several studies have reported the involvement of JAK 
kinase activity in the modulation of PI-3 Kinase function. GM-CSF stimulation of neutro-
phils triggers the activation of Jak2, STAT5, STAT5B, and PI-3K. Treatment of these cells 
with a JAK2 inhibitor AG-490 resulted in abrogation of phosphorylation of the p85 subunit 
of PI-3K in response to GM-CSF stimulation (Al-Shami and Naccache, 1999). Further 
studies indicated that the p85 subunit associated with JAK2 and this interaction was not 
dependent on the two SH2 domain of PI-3K. Also, Yamauchi et al. (1998) using cells 
either deficient in JAK2 or harboring dominant negative JAK2, showed that the insulin-
receptor substrate (IRS) proteins, IRS-1, IRS-2 and IRS-3, are phosphorylated by JAK2. 
Furthermore, these authors elegantly demonstrated that upon phosphorylation by JAK2, 
the phosphorylated IRS proteins serve as scaffolding intermediates to allow docking and 
subsequent activation of PI3-Kinase. Stimulation of cardiac myocytes by LIF promotes 
interaction between JAK1 and PI-3K that leads to increased PI-3K activity in JAK1 immu-
noprecipitates suggesting that JAK1 mediates the activation of the PI3 pathway through 
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the gp130 subunit (Oh et al., 1998). Taken together, these studies indicate that the cel-
lular signal transduction machinery is programmed to respond to changes in stimulus by 
integrating diverse signaling pathways to generate an orchestrated response.
1.10  Phosphatidylinositol-3 Kinase
Phosphatidylinositol-3 kinase (PI3-K) is one of the most important regulatory proteins 
that are involved in different signaling pathways and controlling of key functions of the cell. 
The double enzymatic activity of PI3-K (lipid kinase and protein kinase) as well as the 
ability of this enzyme to activate a number of signal proteins including some oncoproteins 
determines its fundamental significance in regulation of cell functions such as growth 
and survival, aging, and malignant transformation. Among the main effectors of PI3-K are 
the mitogen-transducing signal proteins (protein kinase C, phosphoinositide-dependent 
kinases, small G-proteins, MAP (mitogen activated protein) kinases), which are acti-
vated either via their interaction with lipid products of PI3-K or through PI3-K-dependent 
phosphorylation of proteins. The anti-apoptotic effect of PI3-K is realized by activation of 
proteins from another signaling pathway—protein kinase B(PKB) and/or PKB-dependent 
enzymes (GSK-3, ILK). PI3-K plays a critical role in malignant transformation. PI3-K itself 
possesses oncogenic activity and also forms complexes with some viral or cellular onco-
proteins (src, ras, rac, alb, T-antigen), whose transforming activities are realized only in 
presence of PI3-K. The transforming effect of PI3-K is supposed to occur on the basis of 
complex alterations in cellular signaling pathways: appearance of constitutively generated 
PI3-K-dependent mitogen signal and activation of some protooncogenes (src, ras, rac, 
etc.), PI3-K/PKB-pathway stimulation resulting in delay of apoptosis and increase of cell 
survival, and actin cytoskeleton reorganization.
Initially PI3-K was the subject of interest because of its known ability to form complex-
es with some viral oncoproteins such as v-src and v-ros (Macara et al., 1984; Sugimoto et 
al., 1984) and also because of involvement of intracellular PI3-K in the viral transformation 
process (Cantley et al., 1991). Later, in 1997, the possibility of malignant transformation of 
cells as the result of transfection with DNA containing a fragment of a viral or cellular PI3-
K gene was shown (Chang et al., 1997). Parallel investigations of biochemical properties 
of PI3-K led to rather unexpected results. The two-subunit (regulatory p85 and catalytic 
p110) molecule of PI3-K appears to possess both lipid kinase and protein kinase activ-
ity (Carpenter et al., 1993b). Activation of the dimeric p85/p110 PI3-K molecule occurs 
through phosphorylation of a tyrosine residue by either receptor (platelet, insulin-like, or 
epidermal growth factor receptors) or non-receptor (p60-src) tyrosine kinases (Fukui and 
Hanafusa, 1989; Ruderman et al., 1990; Kapeller and Cantley, 1994). Experiments with 
the use of some specific inhibitors of PI3-K and/or cell transfection with different PI3-K 
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gene variants reveal PI3-K being a mediator in the control of at least two very important 
cell functions, namely, cell division (as a necessary component of the signaling pathway 
initiated by growth factors) and apoptosis (the progress of which is inhibited by PI3-K) 
(Cantley et al., 1991; Scheid et al., 1995).
Recently, clear progress in the investigation of the mechanism of PI3-K action has 
revealed the main mediators of its action. For instance, the event cascade leading to the 
delay of apoptosis is initiated by complex formation between Ptdlns-phosphate products 
of the PBK-catalyzed reaction and protein kinase B (PKB), also named Akt or Akt/PKB) 
(Franke et al., 1997; Klippel et al., 1997). The latter enzyme plays an important role in 
the regulation of the activity of many genes controlling, directly or indirectly, the apoptotic 
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process (Kauffmann-Zeh et al., 1997; Khwaja et al., 1997; Kulik et al., 1997). PI3-K-medi-
ated transduction of mitogen signal is realized in another way. In spite of the traditional 
view of Ptdlns and its derivatives as the main components of mitogen signal, the role of 
PI3-K in the regulation of cell division appears not to be restricted to synthesis of these 
compounds. Not so long ago it was shown that PI3-K might directly control the activities 
of individual components of the RAS/RAF/ERK-mitogenic pathway by complex formation 
with some signal proteins; the enzyme acts in this case as a serine-threonine protein ki-
nase (Carpenter et al., 1993b; Dhand et al., 1994; Bondeva et al., 1998).
Among the other important PI3-K functions involved directly or indirectly in mitogen 
signal transduction, the involvement of PI3-K in receptor down-regulation (endocytosis 
and degradation of activated growth factor receptors), in control of lysosomal enzyme 
synthesis (Joly et al., 1994; Brown et al., 1995), and in reorganization of actin cytoskel-
eton during the course of malignant transformation process and/or mitogen stimulation of 
cells should also be emphasized (Rodriguez-Viciana et al., 1997).
In general, PI3-K is now considered as one of the most important regulatory proteins, 
being involved in a number of diverse signaling pathways and controlling the main func-
tions of the cell. PI3-K activation in malignant cells after exposure to radiation or other 
stress (Carpenter et al., 1990; Kapeller and Cantley, 1994) and also the above-mentioned 
anti-apoptotic effect of PI3-K indicate the important role of this enzyme in the control of 
both malignant cell resistance to damaging agents and the sensitivity of malignant tumors 
to chemo or radiotherapy.
1.11  PI3-K: Structure and General Properties
Phosphatidylinositol-3 kinase is a heterodimer of two subunits, catalytic and regula-
tory, with molecular weights of 110 kD (p110) and 85 kD (p85), respectively (Carpenter et 
al., 1990; Kapeller and Cantley, 1994). Cloning experiments with the use of PI3-K cDNA 
have revealed at least five isoforms of each subunit (Escobedo et al., 1991; Skolnik et al., 
1991; Pons et al., 1995; Inukai et al., 1996). The regulatory p85 subunit consists of several 
domains including the SH3 domain, two proline rich fragments, and two SH2 domains 
separated by the iSH2 (inter SH2) sequence (Fig. 8). The iSH2 domain provides the inter-
action between the p85 and p110 subunits, and the two SH2 domains are responsible for 
binding of the p85/p110 heterodimer with receptor tyrosine kinases (Kapeller and Cantley, 
1994; Yu et al., 1998). It is supposed that due to the ability of the regulatory p85 subunit to 
interact with both the catalytic p110 subunit and receptor tyrosine kinases directed mem-
brane targeting of p110 occurs, initiating complex formation between the enzyme and its 
phospholipid substrate (Skolnik et al., 1991; Kapeller and Cantley, 1994).
The catalytic p110 subunit of PI3-K is homologous to protein kinases and pos-
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sesses both serine-threonine protein kinase and phosphoinositide kinase activities 
(Whitman et al., 1988; Auger et al., 1989; Carpenter et al., 1990; Carpenter et al., 1993b). 
Phosphorylation of Ptdlns and phospho-inositides PtdIns(4)P and PtdIns(4,5)P2 occurs 
in the D3-position of the inositol ring leading to formation of PtdIns(3)P, PtdIns(3,4)P2, 
and PtdIns(3,4,5)P3, respectively. Three classes of the PI3-K protein superfamily are 
now known. All of these possess the protein kinase activity; the difference is preferen-
tially in the substrate specificity of the phosphoinositide kinase site. Thus, the first class 
includes p85/p110 heterodimers reacting with all phosphoinositides, Ptdlns, PtdIns(4)P, 
and PtdIns(4,5)P2. These are now often referred to as phosphoinositide-3 kinases; the 
term reflects their substrate specificity more correctly than the traditional name, phospha-
tidylinositol-3 kinases. The second class involves enzymes phosphorylating preferably 
Ptdlns and PtdIns(4)P. Finally, the third class includes PI3-K that possesses additionally 
a specific protein transfer function and has a structural and functional resemblance with 
the yeast analog of PI3-K, vps34p (vacuolar protein sorting). Unlike the enzymes from the 
first and the second classes, this one uses only Ptdlns as a substrate (MacDougall et al., 
1995; Stoyanov et al., 1995).
Two main processes lead to PI3-K activation: p85/p110 heterodimer assembly and 
interaction of the heterodimer with activator proteins. As mentioned above, the binding of 
the catalytic and regulatory subunits occurs via the iSH2 domain of the latter. The p85/
p110 heterodimer assembly does not result itself in marked enzyme activation. Moreover, 
some investigators reported the activity of the catalytic subunit being decreased when 
the p85/p110 complex is formed in vitro (Yu et al., 1998). An additional interaction with 
specific activator proteins is required for the subsequent activation of the heterodimer 
GP110
iSH2
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PRD
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P P
SH2 SH2
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Fig. 7  Schematic structure of the PI3-K p85/
p110-heterodimer. 
The regulatory p85 subunit consists of (from 
the N-terminus) SH3-domain, two PRDs (pro-
line rich domain), separated by BCR-homolo-
gous domain (BCR, breakpoint cluster region), 
and two SH2-domains, separated by the iSH2 
(inter SH2)-sequence, which is responsible for 
binding with the p110 subunit. Arrows show the 
binding sites of heterodimer to the main PI3K 
activators: phosphotyrosine proteins (P) and 
small G-proteins (G).
22
Introduction
(Backer et al., 1992; Carpenter et al., 1993a; Rordorf-Nikolic et al., 1995). The main acti-
vator proteins have tyrosine-phosphorylated amino acid sequences including both some 
receptor (receptors of platelet, epidermal, or insulin-like growth factors), and non-receptor 
(p60-src) tyrosine kinases (Fukui and Hanafusa, 1989; Ruderman et al., 1990; Kapeller 
and Cantley, 1994). The binding of phosphotyrosine sites of activator proteins with SH2 
domains of the PI3-K regulatory subunit causes a conformational change of the heterodi-
mer leading to enzyme activation (Yu et al., 1998). There are, however, other mechanisms 
of PI3-K activation. An extra activation of the heterodimer may occur while direct interac-
tion between the PI3-K catalytic subunit and one of several cellular proteins takes place. 
A good example is the complex formation between p21-ras and p110 resulting in activa-
tion of PI3-K (Kodaki et al., 1994; Rodriguez-Viciana et al., 1994; Rodriguez-Viciana et 
al., 1996). The diversity of ways for PI3-K activation to occur and also the multi-substrate 
specificity and double-enzymatic activity (lipid kinase and protein kinase) of the enzyme 
likely determine its key role in the control of cell growth and survival.
1.12 Position of PI3-K among General Signaling Pathways
Investigations of recent years have shown the involvement of PI3-K in the control of 
cell division being realized through at least two possible mechanisms: the first includes 
phosphoinositide production (PI3-K lipid kinase activity), the second includes direct in-
teraction of PI3-K with some cellular signal proteins, when the protein kinase activity of 
PI3-K may play a critical role (Whitman et al., 1988; Auger et al., 1989; Carpenter et al., 
1990; Carpenter et al., 1993b; Dhand et al., 1994).
Traditional opinions concerning the role of phosphoinositides in cell growth control 
were based on their role as substrates of phospholipase C, the enzyme that is activated 
by receptor tyrosine kinases during cell division. When accumulated in the cells due to 
phospholipase C action, the hydrolysis products of phosphoinositides (diacylglycerol and 
inositol phosphates) activate protein kinase C, thus stimulating one of the most impor-
tant signaling pathways of the cell (Hug and Sarre, 1993; Cazaubon et al., 1994; Orr and 
Newton, 1994).
However, as was shown later, the phosphoinositides may have an independent sig-
nificance in mitogen signal transduction, because of their ability for direct interaction 
with some signal proteins. The role of phosphoinositides in activation of protein kinase B 
(PKB), which is involved preferentially in the control of cell apoptosis, will be considered 
below. As for the protein mediators of cell division, protein kinase C (PKC) should be dis-
tinguished first of all. The PKC activation appears to occur not only via binding with diacyl-
glycerol formed by hydrolysis of phospholipids, but also via the interaction with PI3-K lipid 
products (Carpenter and Cantley, 1996). Great progress in the study of the control mech-
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anisms of PI3-K was achieved following the discovery of a new family of serine-threonine 
protein kinases, phosphoinositide-dependent kinases (PDK) (Alessi et al., 1997; Alessi 
et al., 1998). These are activated by the lipid products of PDK, 3OH-phosphoinositides 
(hence the name of the family), and responsible for the phosphorylation and activation of 
a number of signaling protein kinases, including both PKB and PKC (Alessi et al., 1997; 
Alessi et al., 1998; Le Good et al., 1998). Thus, two steps of PI3-K-dependent activation 
of protein kinase C may be distinguished: PKC interaction with diacylglycerol, the phos-
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Fig. 8. The involvement of PI3K in the control of intracellular signaling pathways. 
PI3K is activated via interaction with receptor (growth factor receptors) or non-receptor (p60-src) ty-
rosine kinases. Among the main “down-stream” effectors of PI3K are: PKB, responsible for anti-apoptotic 
signal transduction; RAS/ERK, the main mitogen-conducting pathway; RAC/JNKK/JNK, pathway partially 
controlling the mitogen signal transduction but involved mainly in control of other cell functions, such as 
stress reaction or actin cytoskeleton reorganization.
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phoinositide hydrolysis product, and phosphorylation of PKC by PDK family enzymes. 
Also, the data obtained from the studies on binding of phosphoinositides with SH2-con-
taining proteins should be taken into account. These indicate one of the PDK products, 
PtdIns(3,4,5)P3, interacts with SH2-domains of proteins competing with phosphotyrosine 
peptides (Rameh et al., 1995). The same effect may exist for an additional pathway of ac-
tivation of SH2-containing signaling proteins, which is independent from receptor tyrosine 
kinases.
The subject of particular interest is the involving of PDK in receptor “down-stream” 
processes, including endocytosis and degradation of activated growth factor receptors. 
As known, binding of ligand with growth factor receptor and activation of its phosphotyro-
sine kinase domain is followed by internalization of the receptor into intracellular vesicles 
and its consequent degradation in lysosomes (Chang et al., 1993; Lamaze and Schmid, 
1995; Opresko et al., 1995). The whole process and, in particular, the activated recep-
tor transfer into lysosomes appear to be under PDK control (Joly et al., 1994; Joly et al., 
1995). For instance, the studies on the down-stream handling of platelet growth factor 
receptor have revealed that some mutations in the phosphotyrosine site of the receptor 
molecule responsible for PDK binding may cause an almost total blockage of the recep-
tor transfer into lysosomes (Joly et al., 1994). The same effect is caused by wortmannin, 
a specific PDK inhibitor (Joly et al., 1995). However, PDK possesses an ability to direct 
control of lysosomal enzyme activity by stimulation of the transfer of de novo synthesized 
hydrolases into lysosomes (Brown et al., 1995).
The ability of PDK to direct binding with some cellular proteins and also the fact that 
the enzyme possesses not only lipid kinase, but also protein kinase activity opened new 
opportunities for studying its role in intracellular signaling pathways. The p85/p110 het-
erodimer in vivo forms complexes with a broad spectrum of cellular molecules including 
tyrosine kinases, Grb2, p21-ras, rac, Cdc42, tubulin, etc. (Wennstrom et al., 1994c; Zheng 
et al., 1994; Hawkins et al., 1995b; Nobes et al., 1995; Tolias et al., 1995). The subject of 
principal significance for understanding the role of PI3-K in the control of RAS/RAF/ERK 
signaling pathway is complex formation between the catalytic subunit of PI3-K and p21-
ras. PI3-K binds only with the GTP-form of ras resulting in PI3-K activation observed both 
in vitro and in vivo. The same PI3-K activation effect occurs when the heterodimer p85/
p110 binds some other G-proteins, for instance, rac or Cdc42 (Wennstrom et al., 1994c; 
Zheng et al., 1994; Hawkins et al., 1995b; Nobes et al., 1995; Tolias et al., 1995). And, 
on the other hand, complex formation between PI3-K and p21-ras is accompanied by an 
increased amount of activated (GTP-bound) form of ras (Hu et al., 1992). Moreover, the 
presence of PI3-K appears to be necessary both for stimulation of the RAS/RAF/ERK 
pathway and for induced transformation of cells, and, in addition, in some cases PI3-K 
activity inhibition may cause total blockage of transformation (Rodriguez-Viciana et al., 
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1997). It should be mentioned that the mutual control between PI3-K and p21-ras is rather 
complex and does not corresponded to a linear model of mitogen signal transfer. PI3-K 
is supposed to activate p21-ras (possibly via membrane targeting of SOS-proteins) and 
is activated simultaneously via its binding with the GTP-form of ras or other G-proteins 
(Carpenter and Cantley, 1996).
However, the significance of PI3-K for the RAS/RAF/ERK signaling pathway is not 
limited by its influence on p21 -ras. Recently, the important role of serine-threonine pro-
tein kinase activity of PI3-K in the control of cellular MAP-kinases was demonstrated. 
Experiments using different classes of PI3-K whose lipid and protein kinase activ-
ity components differ revealed that only the protein kinase activity of PI3-K causes the 
activation of cellular MAP-kinases (Bondeva et al., 1998). The level of the synthesis of 
phosphoinositides (lipid products of PI3-K) did not influence markedly the MAP-kinase 
activities (Bondeva et al., 1998). Thus, the general scheme of PI3-K-dependent control 
of cellular mitogen-transduction signaling pathways consists of several stages, the main 
being: PI3-K activation via the binding of p85/p110 heterodimer with tyrosine-phos-
phorylated proteins and/or small G-proteins (p21-ras, rac, Cdc42); the synthesis of 3-OH 
phosphoinositides which are the sources of both diacylglycerol and inositol phosphates 
and activators of some protein kinases (PKB, PKC, PDK) they can directly interact with; 
serine-threonine phosphorylation of secondary PDK messengers and the activation of 
MAP-kinases (Fig. 9). Also, the scheme of PDK involvement in cellular metabolism should 
be supplemented with PDK-dependent control of stress-activated signaling pathways.
1.13  Evidence for a Role of PI3-K in Cell Migration
Elegant molecular and pharmacological evidence first suggested that PI3-K and its 
lipid products might play an important role in platelet-derived growth factor (PDGF)-depen-
dent actin polymerization and cell migration.(Kundra et al., 1994; Wennstrom et al., 1994a; 
Wennstrom et al., 1994b; Hawkins et al., 1995a). Moreover, selective activation of PI3-K 
using constitutively active PI3-K mutants or the addition of exogenous Ptdlns(3,4,5)P3 
can initiate cell motililty and membrane ruffling (Reif et al., 1996; Derman et al., 1997). 
However, the very first evidence for the involvement of PI3-K in chemokine-stimulated cell 
migration was the demonstration that chemotaxis and polarization of T cells induced by 
Regulated on Activation, Normal, T-cell Expressed, and Secreted (RANTES)/CCL5 could 
be inhibited by PI3-K inhibitors such as wortmannin and LY294002. Subsequent studies 
by several groups have shown that other CC chemokines (e.g. macrophage inflamma-
tory protein [MIP]-3α/CCL20 and monocyte chemoattractant protein [MCP]-1/CCL2) as 
well as CXC chemokines (e.g. interleukin [IL]-8/CXCL1 and stromal-cell-derived factor 
1 [SDF]-1/CXCL12) stimulate wortmannin-sensitive chemotaxis of eosinophils, THP-1 
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cells, as well as neutrophils and   T lymphocytes, respectively (Knall et al., 1997; Turner et 
al., 1998; Sotsios et al., 1999; Sullivan et al., 1999). It seems probable that the production 
and degradation of 3’-phosphoinositide lipids is crucial in maintaining chemotactic signal-
ling gradients. This interpretation was reinforced by subsequent evidence from mice defi-
cient in SHIP (Src homology 2 [SH2]-containing inositol 5-phosphatase), an enzyme that 
hydrolyses PtdIns(3,4,5)P3. These SHIP
-/- mice suffer from lethal infiltration of the lungs 
by macrophages and neutrophils and therefore persistently high levels of PtdIns(3,4,5)P3 
and subsequent activation of its downstream effectors might lead to excessive inflam-
mation (Helgason et al., 1998). Finally, elegant studies using green fluorescent protein-
tagged PH domains that bind selectively with PtdIns(3,4,5)P3 and PtdIns(3,4)P2 revealed 
that Ptdlns(3,4,5)P3 accumulated at the leading edge of chemoattractant-stimulated HL-
60 cells (Servant et al., 2000). Similarly, PtdIns(3,4,5)P3 localization at the leading edge 
of polarized cells was observed using a PtdIns(3,4,5)P3-specific antibody (Ab) (Rickert 
et al., 2000) This accumulation of PtdIns(3,4,5)P3 at the leading edge correlates with the 
polarization of chemokine receptors that are involved in detecting a chemoattractant gra-
dient.
1.14  PI3-K Activation Regulate Cell Migration
Reorganization of the actin cytoskeleton is an important step in cell migration, and 
different chemokines are able to induce the polarization of lymphocytes with genera-
tion of specialized cell compartments. Given that Rho GTPases Rho, rac and Cdc42 are 
regulators of actin cytoskeleton and cellular polarity, there has been much interest in 
ascertaining the role of the Rho GTPases in chemokine signalling and their relationship 
with the PI3-K-dependent signalling cascade (Hall, 1998). Indeed, there is considerable 
evidence to indicate that Rho family kinases are regulated by PI3-K in several systems. 
For instance, Rac and Cdc42 have been reported to associate with p85/p110 (Tolias et 
al., 1995), whilst expression of active mutants of p110α in fibroblasts can induce actin 
reorganization in the form of Rac-mediated lamellipodia and focal complexes and Rho-
mediated stress fibres and focal adhesions (Reif et al., 1996). Similarly, reorganization 
of the actin cytoskeleton and membrane ruffling induced by overexpression of wild-type 
PI3-Kγ or expression of an active mutant of PI3-Kγ required Rac but not Cdc42 (Reif et 
al., 1996), whilst the PI3-K homologue TOR2 controls Rho activation in Saccharomyces 
cerevisiae (Ma et al., 1998) PI3-K has been shown to be involved in the regulation of actin 
cytoskeleton by growth factors such as PDGF and insulin (Kotani et al., 1994).
Cdc42 appears to have a major role in the control of directional migration of leuco-
cytes, as a dominant-negative mutant of Cdc42 displays a much more potent inhibitory 
effect on leukaemic T-cell line chemotaxis towards SDF-1 gradients than dominant-nega-
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tive mutants of RhoA and Rac (del Pozo et al., 1999). In addition, expression of Cdc42 
mutants in monocytic cells demonstrated that rearrangement of the actin cytoskeleton in 
response to CC chemokines (MCP-1 and MIP-1α) is regulated via Cdc42 (del Pozo et 
al., 1999). Interestingly, MCP-1 and MIP-1α but not Cdc42-stimulated cytoskeletal reor-
ganization, can be inhibited by wortmannin, indicating the involvement of PI3-K upstream 
of Cdc42 in chemokine-stimulated cell migration (Weber et al., 1998). There are also 
remarkable similarities between the phenotype of mice lacking the small GTPases Rac2 
(which in mammals is usually restricted to expression in haematopoietic cells) and that of 
the PI3-Kγ-deficient phenotype. Hence, Rac2-deficient animals have a higher leucocyte 
blood count, their leucocytes are less able to infiltrate the peritoneum in experimental in-
flammatory models and less able to migrate in vitro in response to chemoattractants such 
as fMLP and IL-8 (Roberts et al., 1999). The overlap of phenotypes suggests that Rac2 
may be in the same leucocyte signalling pathway as PI3-Kγ. However, whilst the effect of 
chemokines on Rac activation was not assessed, it should be noted that Rac activation 
in response to the non-chemokine chemoattractant fMLP still occurs in POKγ-deficient 
cells. One probable explanation for this, however, is that fMLP stimulation of the p85/p110 
heterodimer is able to sustain coupling to Rac in PHKγ-deficient mice (Stephens et al., 
1993).
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2  Materials and Methods
2.1 Materials
Chemicals of high quality commercial grade were purchased from Sigma-Aldrich 
(St.Louis, MO, USA), Amersham Pharmacia Biotech (Piscataway, NJ, USA), Merck 
& Company (West Point, PA, USA), Serva Biochemicals (Hauppauge, NY, USA). 
Radiochemicals and chemiluminescent signal enhancers were obtained from NEN 
Reseach Products, Dupont (Hertfordshire, UK). Vectashield mounting medium was pur-
chased from Vector Laboratories (Burlingame, CA, USA). GST-(PI3-K)-p85-N-SH2 do-
main (amino acids 333-428) and GST-(PI3-K)-p85-C-SH2 domain (amino acids 624-718) 
were obtained as an agarose conjugate from Upstate Biotechnology (UBI)  (Walham, 
MA, USA). Wortmannin and LY294002 were from Sigma-Aldrich; uPA and ATF were from 
American Diagnostica (Greenwich, CT, USA). Restriction endonucleases HindIII, XbaI, 
PacI, EheI, and T4 DNA ligase were from New England BioLabs (Beverly, MA, USA); the 
Expand High Fidelity PCR system was from Roche Diagnostics (Indianapolis, IN, USA); 
plasmid pCR2.1TOPO was purchased from Invitrogen (Carlsbad, CA, USA); and plas-
mids pTGBKCMV and pAD1 were from HepaVec (Berlin, Germany), Plasmid pBluescript 
II SK- was bought from Stratagene (La Jolla, CA, USA).  Reagents for cultivation E. Coli 
cells were purchased from Difco Laboratoris, division Becton Dickinson (Franclin Lakes, 
NJ, USA).
2.2 Antibodies
Mono- and polyclonal anti-STAT1 phosphotyrosine and phosphoserine antibodies 
were from Affinity Research Products Ltd. (Exeter, UK) and Pierce Chemical (Rockford, 
IL, USA); mono- and polyclonal anti-p85 PI3-K antibodies were from BD Transduction 
Laboratories (Lexington, KY, USA) and Upstate Biotechnology (UBI) (Waltham, MA, 
USA) Mono- and polyclonal anti- Janus kinases antibodies were purchased from BD 
Transduction Laboratories and Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
uPAR (CD87) monoclonal antibody was purchased from American Diagnostica, Inc. 
(Stamford, CT, USA). Peroxidase-conjugated affinipure goat anti-mouse and goat anti-
rabbit IgG and Cy3-conjugated anti-rabbit and anti-mouse IgG were purchased Jakson 
Immunoresearch Laboratoris (West Grrove, PA, USA). Alexa 488-conjugated phalloidin 
was from Molecular Probes, Inc. (Eugene, OR, USA). 
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2.3 Cell Culture and Cell Treatment
2.3.1 Cell Culture
Human VSMC from coronary artery were obtained from Clonetics (Walkersville, MD, 
USA). The cells were grown in SmGM2 medium (Clonetics) supplemented with 5% fetal 
calf serum (FCS) and were used between passages 5 and 7. For uPA stimulation experi-
ments, the cells were cultured for 24 h in serum-free medium and were then treated with 
uPA as described below. Human transformed kidney epithelial cells HEK 293 were ob-
tained from American Type Culture Collection (ATCC) (Manassas, VA, USA). Monocytes 
were isolated from human peripheral blood from healthy volunteers using Biocoll Separation 
Solution (Biochrom, Berlin, Germany) according to the standard protocol. FACS analysis 
using FITC-conjugated mouse anti-human CD14 monoclonal antibody resulted in about 70-
80% CD14 positive cells that were resuspended directly after separation in SmGM medium 
(Clonetics, San Diego, USA) and used for coculture. For the transfilter coculture experiments, 
VSMC were grown up to 30% confluency in 6-well plates. Filter inserts (25 mm diameter, 0.4 
µm polycarbonate membrane; Nunc, Roskilde, Denmark) containing 1.8x106 monocytes were 
transferred into wells containing VSMC and both cell types were cocultivated up to 4 days.
2.3.2 Cell Stimulation 
Subconfluent and serum-starved VSMC were treated with 1 nM uPA for 5-180 min at 
37° C, lysed, and precleared as described in immunoprecipitation protocol. In some ex-
periments, cells were pretreated with 100 nM wortmannin for 20 min at 37° C. 
2.4 Molecular Biology Methods
2.4.1 Bacterial Strains Used for Adevirus Construction
In order to produce and amplify recombinant adenovirus with the adenoviral system, 
two different prokaryotic host strains are required. The first, BJ5183, is recA proficient 
and supplies the machinery necessary to execute the recombination event between the 
shuttle vector and the pHV1 vector. The second strain, DH5α (Clontech Laboratories, 
Palo Alto, CA) competent cells, is used to amplify the recombined adenovirus plasmid. 
2.4.2 The Hanahan Method of Preparation Competent E. Coli
The desired E. coli cell strain were streak directly from a frozen stock on the surface 
of an SOB agar plate (2% bactotryptone; 0.55% yeast extract; 10 mM NaCl; 10 mM KCl; 
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10 mM MgCl2; 10 mM MgSO4; 1.5 % bactoagar, pH 7,6). The plate was incubated for 16 
h at 37° C. Four or five well-isolated colonies were transferred into 1 ml of SOB (2% bac-
totryptone; 0.55% yeast extract; 10 mM NaCl; 10 mM KCl; 10 mM MgCl2, pH 7,6) contain-
ing 20 mM MgSO4.  The bacteria were dispersed by vortexing at a moderate speed, and 
then the culture was diluted in 100 ml of SOB containing 20 mM MgSO4 in a 1-liter flask. 
The cells were grown for 2.5-3.0 h at 37° C, monitoring the growth of the culture E. coli: 
in early- to mid-log phase (OD600 = 0.4). The cells were transferred to sterile, disposable, 
ice-cold 50-ml polypropylene tubes. The culture was cooled  < to 0° C by storing the tubes 
on ice for 10 min. The cells were recovered by centrifugation at 2,700 x g (4,100 rpm in 
a Sorvall GSA rotor) for 10 min at 4°C. The medium was decanted from the cell pellets. 
The pellets were resuspended by swirling or gentle vortexing in ~20 ml (per 50-ml tube) 
of ice-cold FSB (potassium acetate, 10 mM; MnCl2-4H2O, 45 mM; CaCl2-2H2O, 10 mM; 
KCl, 10 mM; hexamminecobalt chloride, 100 mM; Glycerol 10% (v/v); pH 6.4) transforma-
tion buffer. The resuspended cells were stored on ice for 10 min. The cells were recovered 
by centrifugation at 2,700 x g (4,100 rpm in a Sorvall GSA rotor) for 10 min at 4°C. The 
buffer was decanted from the cell pellets. The pellets were resuspended by swirling or 
gentle vortexing in 4 ml (per 50-ml tube) of ice-cold FSB. 140 µl of DMSO was added per 
4 ml of resuspended cells. It was mixed gently by swirling, and the suspension was stored 
on ice for 15 min. An additional 140 µl of DMSO was added to each suspension. It was 
mixed gently by swirling and then the suspensions were returned to an ice bath. Aliquots 
of the suspensions were dispensed into chilled, sterile microfuge tubes or tissue culture 
vials. The competent cells were immediately snap-freezed by immersing the tightly closed 
tubes in a bath of liquid nitrogen. The tubes were stored at -70° C until needed.
2.4.3  Transformation of Competent Cells
The transforming DNA (up to 25 ng per 50 µl of competent cells) was added in a vol-
ume exceeding 5% of that of the competent cells. The tubes were swirled gently several 
times to mix contents. The tubes were stored on ice for 30 min and then were transferred 
to a rack placed in a preheated 42°C circulating water bath. The tubes were stored in the 
rack for exactly 90 sec. The tubes were rapidly transfered to an ice bath for 1-2 minutes. 
800 µl of SOC (SOB plus 20 mM glucose) medium were added to each tube. The tubes 
were transfered to a shaking incubator set at 37° C. The cultures were incubated for 45 
min allowing the bacteria to recover and to express the antibiotic resistance marker en-
coded in plasmid with gently shaking (<225 cycles/min). The appropriate volume (up to 
200 µl per 90-mm plate) of transformed competent cells was transferred onto agar SOB 
medium containing 20 mM MgSO4 and the appropriate antibiotic.
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2.4.4 Small–Scale Preparation of Plasmid DNA
Mini preparations of plasmid DNA were obtained by alkaline lysis method. This proto-
col is a modification of the method of Birboim and Doly (1979) and Ish-Horowitz and Burke 
(1981). Single bacterial colony was transferred into 3 ml of LB (bacto yeast extract, 0.5%; 
bacto tryptone, 2%; MgSO4 0.5%; pH 7.6) medium containing the appropriate antibiotic in 
a loosely capped 15 ml tube. The culture was incubated overnight at 37o C with vigorous 
shaking. The culture was poured into 1.5 ml microfuge tube and centrifuged at 5,000 rpm 
for 5 min in a microfuge. The remainder of the culture was stored at 4o C. The medium was 
removed by aspiration, living the bacterial pellet as dry as possible. The bacterial pellet 
was resuspended in 100 µl of ice-cold Solution I (50 mM glucose; 25 mM Tris-HCl, pH 8.0; 
10 mM EDTA; pH 8.0) by vigorous vortexing. The freshly prepared 200 µl Solution II (0,2 N 
NaOH; 1% SDS (w/v)) was added to cell suspension, mixed contents by inverting the tube 
rapidly five times. The tubes were stored on ice. The ice-cold solution III (5 M potassium 
acetate, 2 M acetic acid) was added to the tubes, which were then vortexed gently in an 
inverted position for 10 sec to disperse Solution III through the viscous bacterial lysate. 
The tubes were stored on ice for 3-5 min. After the centrifugation for 5 min at 13000 rpm, 
4o C the supernatant was transferred to a fresh tube. An equal volume phenol: chloroform 
was added and mixed by vortexing. After centrifugation for 2 min at 13,000 rpm, 4o C in 
a microfuge, the supernatant was transferred to a fresh tube. Double stranded DNA was 
precipitated with 2 volumes ethanol at room temperature. Tubes were spinned for 5 min at 
13,000 rpm, 4o C in a microfuge and the precipitate was rinsed with 1 ml of 70 % ethanol 
at 4o C. The pellet of nucleic acid was dried in the air for 10 min and redissolved in TE (10 
mM Tris-HCl; 1 mM EDTA; pH 8,0) containing DNAase-free pancreatic RNAase (20 µl/ml). 
DNA was stored at –20o C.
2.4.5 RNA Isolation
Total RNA extracted from cultured smooth muscle cells was used as a template in 
reverce transcription reactions. During the work with RNA a series of precautions were 
taken to avoid RNase contamination. Glassware was baked at 200° C for at least 4 h 
and water was treated with DMPC (Dimethylpyrocarbonate). A 10% DMPC stock was 
prepared in ethanol and was then diluted 1:100 in double distilled water, left at room tem-
perature overnight and finally autoclaved.
Total RNA extractions were done with a TRISOL reagent (GibcoBRL). Cells were lysed 
directly in a culture dish by adding 1 ml of TRIZOL reagent to a 3.5 cm diameter dish, and 
passing the cell lysate several times through a pipette. The amount of TRIZOL reagent 
added is based on the area of the culture dish (1 ml per 10 cm2) and not on the number 
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of cells present. The homogenized samples were incubated for 5 min at RT to permit the 
complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added per 1 
ml of TRIZOL Reagent. Tubes were shaked vigorously by hand for 15 sec and incubated 
then at RT for 2 to 3 min. The samples were centrifuged at 12,000 x g for 15 min at 2 to 
8° C. Following centrifugation, the mixture separates into a lower red, phenol-chloroform 
phase, an interphase, and a colorless upper aqueous phase. The volume of the aque-
ous phase is about 60 % of the volume of TRIZOL Reagent used for homogenization. 
The aqueous phase was transferred to a fresh tube. The RNA was precipitated from the 
aqueous phase by mixing with isopropyl alcohol. 0.5 ml of isopropyl was used alcohol per 
1 ml of TRIZOL reagent used for the initial homogenization. Samples were incubated at 
RT for 10 min and centrifuged at  12,000 x g for 10 min at 2 to 8° C. The supernatant was 
removed. The RNA pellet was washed once with 75 % ethanol, adding at least 1 ml of 75 
% ethanol per 1 ml of TRIZOL reagent used for the initial homogenization. The sample 
was mixed by vortexing and centrifuged at 7,500 x g for 5 min at 2 to 8o C. At the end of 
the procedure, the RNA pellet was briefly dried by air or vacuum for 5-10 min. RNA was 
redissolved in 100 % formamide (deionized) and stored at -70° C.
The purity of total RNA was checked by running ~ 1µg of total RNA on a 1 % agarose 
gel made in TAE buffer (40mM Tris-acetate;1mM EDTA, pH 8) with 0,5 µg/ml ethidium 
bromide. The two ribosomal RNA bands (23S and 18S) were clearly detected when the 
gel was viewed under ultraviolet light (UV) and smears (as indicator of RNA degradation) 
were not seen between the two bands. To quantify the total RNA, an aliquot was mea-
sured by UV absorbance at 260 nm (A260) and 280 nm (A280) where the absorbance of 1 in 
a 1 cm path length corresponds to a RNA concentration of 40 µg/ml. The absorbance ratio 
of 260 nm and 280 nm gave an estimate of the purity of the solution. Pure RNA solutions 
had A260/A280 values between 1.7-2.
2.4.6 Reverse Transcription
To assay for Tyk2 gene expression, total RNA from human VSMC was reverse tran-
scribed into cDNA. For this reaction hexamer primers of random sequence as well as 
oligonucleotides of defined sequence were used. The following components were mixed 
in a total volume of 20 µl to perform a reverse transcription reaction: 1 µg of total RNA was 
mixed with 1 x reaction buffer (100 mM Tris/ 500 mM KCI pH 8.3), 5 mM MgCl2, 2-10 pmol 
of primer, 1 mM each dNTP and 20 units of avian myeloblastosis virus (AMV) reverse 
transcriptase enzyme (Roche Molecular Biochemicals). The mixture was then briefly vor-
texed and incubated at 25° C for 10 min to allow the primer to anneal to the RNA, followed 
by incubation at 42° C for 1 h during which the RNA was reverse transcribed resulting in 
cDNA synthesis. The reaction mixture was incubated at 99° C for 5 min to denature the 
AMV enzyme and then the mixture was cooled down to 4°C for 5 min.
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2.4.7 RT-PCR for uPA and uPAR
RT-PCR analysis for uPA and uPAR mRNAs in monocytes and VSMC in coculture 
was performed using the TaqMan method. RNA was isolated using the RNeasy mini 
prep kit (Qiagen, Santa Clarita, USA) and on-column DNase digestion according to 
the manufacturer’s protocol. RNA was eluted from columns in 50 µl RNAse-free water. 
Gene-specific TaqMan primers and probes for human uPA, uPAR and the housekeeping 
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed using Primer 
Express software (PE Biosystems, Foster City, USA), according to the manufactures 
guidelines. All primers and probes were purchased from BioTeZ GmbH (Berlin, Germany), 
with each GAPDH, uPA or uPAR probe being syntesised with a fluorescent 5’-reporter dye 
(FAM; 6-carboxyfluorescein) and 3’-quencher dye (TAMRA; 6-carboxy-tetramethyl-rhoda-
mine). The following primers were used: (a) for uPA, ACTGCAGGAACCCAGACAACC; 
TGGACAAGCGGCTTTAGGC; TaqMan probe AGGCGACCCTGGTGCTATGTGCAG; (b) 
for uPAR, ACCACCAAATGCAACGAGG; GTAACACTGGCGGCCATTCT; TaqMan probe 
CAATCCTGGAGCTTGAAAATCTGCCG; (c) for GAPDH, GAAGGTGAAGGTCGGAGTC; 
GAAGATGGTGATGGGATTC; TaqMan probe CAAGCTTCCCGTTCTCAGCC. Reverse 
transcription reaction and TaqMan PCR reaction were performed according to the single-
tube protocol (PE Biosystems). TaqMan PCR assays for each gene target were peformed 
on total RNA in optical tubes with an ABI Prism 7700 Sequence Detection system (PE 
Biosystems). For each 25 µl TaqMan reaction, 3 µl total RNA was used. Parallel assays were 
run for the housekeeping gene GAPDH in addition to target genes of interest. All TaqMan 
RT-PCR data were captured using Sequence Detector Software (SDS version 1.6; PE 
Biosystems). For each mRNA template, reactions were prepared in triplicates and relative 
quantitation of gene expression was calculated using the comparative C
T
 method for sepa-
rated tubes, according to the standard protocol. Data from each sample were normalized 
by dividing the quantity of target RNA by the quantity of housekeeping mRNA (GAPDH), 
to correct for differences in RNA quantity and quality.
2.4.8 In Vitro Mutagenesis Using Double-Stranded DNA 
Two oligonucleotide primers were used for single point mutation. For the design of oli-
gonucleotide primers were used recomindation of Sratagene Company for QuickChange 
mutagenesis kit.
The template DNA used for mutagenesis was a circular plasmid containing the cDNA 
of interest. In sterile 0.5-ml microfuge tubes, a series of reaction mixtures containing dif-
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ferent amounts (e.g., 5, 10, 25, and 50 ng) of plasmid DNA were set up and a constant 
amount of each of the two oligonucleotide primers.
10x Pfu  polymerase buffer (Stratagene) 5µl
template plasmid DNA 5-50 ng
oligonucleotide primer 1 (20 mM) 2.5 µl
oligonucleotide primer 2 (20 .mM) 2.5 µl
dNTP mix (dNTPs, each at 5 mM) 2.5 µl
H20 to 50 µl
2.5 units of Pfu DNA polymerase  (Stratagene) were added. The tubes were placed 
in the thermal cycler. The nucleic acids were amplified using the denaturation, annealing, 
and polymerization times and temperatures listed in the table.
Cycle Number Denaturation Annealing Polymerization
1 cycle 1 min at 95°C
2-18 cycles 30 sec at 95°C 1 min at 55°C 2 min/kb of plasmid DNA at 68°C
Last cycle 1 min at 94°C 1 min at 55°C 10 min at 72°C
For single-base substitutions, were used 12 cycles of linear amplification; for substitu-
tion of one amino acid with another (usually two or three contiguous base substitutions), 
were used 16 cycles; for insertions and deletions of any size, were used 18 cycles. After 
amplification of the DNA, the reactions were placed on ice. Adding 10 units of Dpnl directly 
to the remainder of the amplification reactions digested the parent’s plasmid DNAs.  The 
reagents were mixed by pipetting the solution up and down several times, the tubes were 
centrifuged for 5 sec in a microfuge, and then were incubated for 1 h at 37°C. Competent 
cells (DH5α strain prepared by Rubidium Chloride method) were transformed with 1, 2, 
and 5 µl of digested DNA according to the procedure described earlier.
2.4.9 Sequencing
Plasmids were sequenced to verify that they contained the desired inserts and to 
control for unwanted mutations. Samples were processed by the dye terminator method 
(Applied Biosystems, division PE Biosystems) and purified from unintercalated labeled 
dNTPs by Centri-Sep spin columns (Applied Biosystems, Foster City, CA). The samples 
were then mixed with 4 ml buffer (deionized formamide and 25 mM EDTA pH 8.0 con-
taining 50 mg/ml Blue dextran in a ratio 5:1 formamide: EDTA-Blue dextran), denatured 
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by heating at 94o C for 4 min, and loaded on sequencing gel on an automated DNA se-
quencer (Applied Biosystems, Foster City, CA). The samples were then separated on a 
polyacrylamide gel and the fluorescent nucleotides excited with a laser beam. The emit-
ted fluorescence was collected by detectors (Applied Biosystems, Foster City, CA) and 
sent to a computer, where the appropriate software converted the data into nucleotide 
sequence. For sequence assembling, editing and alignments, the Lasergene software 
programs EditSeq, SeqMan and MegAlign (DNASTAR, Madison, USA) were used. Some 
samples were sequenced by the InViTek Company (Berlin, Germany).
2.4.10 Probe Labeling 
cDNA fragments subcloned into pCRI2.1TOPO vectors were prepared by restriction 
digestion of plasmids and isolated by gel purification. For radioactive labeling of DNA frag-
ments, the random primer extension kit (Amersham Pharmacia Biotech, Piscataway, NJ, 
USA) was used and the enzyme required for this process was Escherichia coli DNA poly-
merase I (Klenow fragment). The reaction mixture contained: 25 ng of DNA (which has 
been previously gel purified) and 5 µl of random primers (Amersham Pharmacia Biotech), 
which were brought to 50 µl final reaction volume with double distilled water. The initial 
mixture was denatured by boiling for 5 min. Keeping the tube at RT, the unlabeled dNTPs 
(0.1 mM each, omitting those to be used as label) and reaction buffer (from Amersham 
Pharmacia Biotech, containing Tris-HCl pH 7.5, 2-mercaptoethanol and MgCl2) followed 
by the radiolabeled dNTPs and DNA polymerase I (Klenow fragment) enzyme (0.04 units/
µl) were added. The reaction mixture was then incubated at 37o C for 1 h. Phosphorus-la-
beled dNTPs (3000 Ci/mmol [α-32P] dCTP) were used. Non-incorporated labeled nucleo-
tides were removed from the probe by precipitation with 0.1 volume of 4 M LiCl and 2.5 
volumes of chilled absolute ethanol and incubation at –70o C for 30 min and centrifuga-
tion at 13,000 x g for 15 min at 4o C. The pellet was then washed with ~ 100 µl of cold 70 
% ethanol, air dried and dissolved in 20 µl of double distilled water. The efficiency of the 
labeling reaction was monitored by a scintillation counter in multi-sample β-spectrometr 
(Beckman Instruments Inc., Palo Alto, CA, USA).
2.4.11 RNA Preparation, and Northern Blotting
VSMC were grown to 50% confluence and infected for 1h with recombinant AdTyk2 or 
AdTyk2KE adenovirus stock at a multiplicity of infection of 500 plaque-forming units/cell 
(PFU). Immunological staining with anti-Tyk2 antibody assessed the efficiency of infec-
tion. Cells were serum-starved overnight 1 day after infection and used for total RNA 
preparation on the second day after infection. Total RNA was prepared from VMSC using 
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standard protocol with TRIZOL reagent from Life Technologies (Rockville, MD, USA). The 
RNA was subjected to electrophoresis through an agarose-formaldehyde gel, transferred 
to a gene-screen plus membrane (DuPont NEN Products, Boston, MA, USA), and hybrid-
ized with nick-translated BamHI fragment from Tyk2 cDNA as described (Maniatis et al, 
2000). An actin probe was used to confirm equal RNA loading on the gel. 
2.5 Biochemical Methods
2.5.1 Protein Determination by Bradford Method
96 microwell plate (Macrowell Plate, Nunc,Naperville, IL, USA) was used. The diluted 
samples of BSA at concentrations of 4 - 40 µg/ml for the standard curve and of unknown 
protein were added to the wells in a volume of 50 µL. 200 µl of Bradford reagent Protein 
Assay Dye ((Bio-Rad Laboratories, Hercules, CA, USA) at a dilution with water of 1:5 
were added per well for 5 min. Each sample was measured in triplicates. The absorption 
was measured at 595 nm using a microplate reader ThermoMax from Molecular Devices 
(Sunnyvale, CA, USA). The software SOFTmax PRO was used.
2.5.2 Tyrosine Phosphorylation, Western Blotting
Subconfluent and serum-starved human VSMC were washed twice with HEPES-NaCl 
buffer (10 mM HEPES, pH 7.5; 150 mM NaCl) and then treated with 1 nM uPA (Sigma) 
or 1 nM ATF (kindly provided by Dr J. Henkin, Abbott Laboratories, Abbott Park, USA) at 
37° C for 5 to 30 min. Cells were put on ice; washed with ice-cold, HEPES-buffered saline 
containing 0.3 mM sodium orthovanadate, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leu-
peptin, 0.1 mM quercetin, and 0.1 mM N-carbobenzyloxy-L-phenylalanine chloromethyl 
ketone; and harvested by scraping. After centrifugation (1,500 x g, 3-5 min, 4o C), the pel-
lets were lysed in lysis buffer (20 mM Tris-HCl, pH 8.0; 138 mM NaCl; 10% glycerol; 2 mM 
EDTA; 1% Triton X-100; and protease inhibitors as indicated above) and left on ice for 10 
min. Lysates were sonicated at maximum intensity for two 10 sec periods and centrifuged 
(8 min at 15,000 x g, 4o C). Supernatants were used for polyacrylamide gel electrophore-
sis (PAGE) and Western blotting. The blots were developed with the appropriate antibody; 
the immune complexes were visualized by an enhanced chemiluminescence detection 
system Pierce Chemical (Rockford, IL, USA).
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2.5.3  Immunoprecipitation
For immunoprecipitation, cell lysates containing 600 to 1000 µg protein were pre-
cleared for 2 h at RT with Gamma-Bind Sepharose (Amersham Pharmacia Biotech) 
and then immunoprecipitated overnight at 4° C by using 5 or 10 µg polyclonal antibody 
coupled to protein A–agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For 
monoclonal antibody protein A-agarose were replased by protein G-agarose (Santa Cruz 
Biotechnology). Precipitates were washed three times in PBS buffer (137 mM NaCl; 2,7 
mM KCl; 10 mM Na2HPO4; 1,8 mM KH2PO4; pH 7,4) with 0,05% (v/v) Tween20 (PBS-
T0.05%). Precipitated proteins were eluted with Laemmli sample buffer (1% SDS, w/v; 11% 
glycerol, w/v; 125 mM DTT; 0.01% bromophenol blue, w/v; 50 mM Tris-HCI, pH 6.8; 95o C, 
5 min) and were used for PAGE and Western blotting.
2.5.4  SDS-Polyacrylamide-Gel-Elektrophoresis (SDS-PAGE)
The standard Laemmli (Laemmli, 1970) method was used for discontinuous gel elec-
trophoresis under denaturing conditions, that is, in presence of sodium dodecyl sulfate 
(SDS). The standard method for full-size (e.g., 14x14 cm) was adapted for the minigel 
format (7x10 cm).  Assemble the glass plate sandwich of the electrophoresis apparatus 
was done according to manufacturer’s instruction used two clean glass plates and two 
1-mm spacers. The desired percentage of acrilamide in separating gel depends on the 
molecular size of the protein being separated.  The 3% stacking (125 mM Tris-HCl, pH 6,8; 
3% (v/v) acrilamide/bisacrilamide (37,5:1); 0,1 %(w/v) SDS; 0,1% (w/v)  APS  and 0,05 % 
(v/v) TEMED) and 10 % separating gel (375 mM Tris-HCl, pH 8,8; 10% (v/v) acrilamide/
bisacrilamide (37,5:1); 0,1 %(w/v) SDS; 0,1% (w/v) APS  and 0,05 % (v/v) TEMED) were 
used for usual procedure. Gel run was carried out in electrophoresis camera Mini-Protean 
II with Power Supplier model 1000/500 Bio-Rad Laboratories (Hercules, CA, USA) at con-
stant current 20 mA per gel. 
2.5.5 Semi-dry Blotting
The electrotransfer of proteins from polyacrylamid gel to PVDF membrane (Roche 
Diagnostics, Indianapolis, IN, USA) was performed in semi-dry modification in Trans-Blot 
SD apparatus with Power Supplier model 1000/500 (Bio-Rad Laboratories, Hercules, CA, 
USA) at 110 mA per blot-sandwich (50 min) with transfer buffer (Tris 48 mM; Glycin 39 
mM; SDS 0,037 % (w/v); Methanol 20% (v/v)).
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2.5.6  Immunologic Detection of Transferring Proteins 
Immobilized proteins were probed with specific antibodies to identify and quantitate 
any antigenic presents. The membrane was immersed in blocking buffer (PBS-T0.05%, 1% 
BSA (w/v), RT, 1h) to fill all protein-binding sites with a nonreactive protein or detergent. 
Next, it was placed in solution containing the antibody (in PBS-T0.05%, 1% BSA (w/v), RT, 
2h or 4o C overnight) directed against the antigen. 
The blot was washed 10 min, three times with PBS-T0.05%, and exposed for 1h the per-
oxidase-antibody conjugate directed against the primary antibody (secondary antibody in 
PBS-T0.05%, 1% BSA (w/v), RT, 1h). Membrane was washed as describe above. Antigens 
were identified by luminescent visualizations. After the final wash, the blot was immersed 
in substrate solution (Renaissance© , DuPont NEN, Boston, MA, USA) containing lumi-
nol for horseradish peroxidase (HRPO) systems, sealed in thin plastic wrap, and placed 
against film Kodak X-Omat Blue XB-1 (Eastman Kodak Company, Rochester, NY, USA).
2.5.7  Reprobing of PVDF- Blotmembrane
“Stripping” of the membranes was performed with 200 mM β-mercaptoethanol, 62.5 
mM Tris-HCl (pH 6.8), and 2% SDS (w/v) for 45 min at 50°C. Membrane were washed 
three times in PBS-T0.05%, blocked in 3% (w/v) BSA (1h, RT), and used for immunoblotting 
as indicated above.
2.5.8  In Vitro Phosphorylation Assay and Reimmunoprecipitation
For the in vitro phosphorylation assay, 400-800 µg of protein of precleared cell lysates 
were incubated with 4-5 µg of the indicated antibody coupled to the protein A-agarose for 
2 h. Precipitates were washed four times with lysis buffer and twice with kinase buffer (20 
mM HEPES, pH 7.4, 10 mM MgCl2, 5 mM MnCl2, 1 mM dithiothreitol,
 300 µM sodium or-
thovanadate, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride). The kinase assay 
was performed in 40 µl of kinase buffer containing 3-5 µCi of [α-32P]ATP (3000 Ci/mmol) 
for 10 min at 30° C. Precipitates were washed once with lysis buffer and twice with PBS-
Tween buffer. The phosphorylated products were eluted in 150 µl of lysis buffer contain-
ing 0.5 % SDS and 5 mM sodium orthovanadate and then subjected to a second round 
of immunoprecipitation with 1 µg of the indicated antibody coupled to protein A-agarose 
overnight at 4° C. Phosphorylated proteins were analyzed by SDS-PAGE and autoradiog-
raphy. In some experiments, gels containing phosphorylated proteins were soaked in 1 N 
KOH at 55° C for 2 h to hydrolyze phosphate on serine and threonine. 
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2.5.9 PI3-K Assay
Precleared cell lysates containing 600-800 µg of protein were incubated for 2 h at 4° C 
with 4 µg of anti-PI3-K antibody against the p85 regulatory subunit and then precipitated 
on protein A-agarose. Precipitates were washed once with lysis buffer containing 300 µM 
sodium orthovanadate and 1 mM phenylmethylsulfonyl fluoride and then four times with 
10 mM HEPES, 100 mM NaCl, pH 7.4, and then subjected to the in vitro kinase reaction in 
a final volume of 50 µl of reaction mixture containing 1 mg/ml L-phosphatidylinositol, 3 mM 
MgCl2, 15 mM ATP, and 3-5 µCi of [α-32P] ATP (3000 Ci/mmol) for 10 min at 30° C. Phase 
separation of lipids was performed in two steps by n-hexane/isopropyl alcohol (26:14) and 
2N KCl/HCl (8:0.25). Phosphorylated lipids were separated by thin layer chromatography 
on aluminum sheets silica gel 60W (Merck, Germany) in chloroform/methanol/H2O/25% 
ammonium (45:35:7.5:2.8; v/v/v/v) and visualized by autoradiography. 
2.5.10  Fusion Protein Precipitation Assay
GST fusion proteins containing the single C- or N-terminal p85 SH2 domain (GST-
p85-C-SH2 and GST-p85-N-SH2) bound to glutathione-agarose beads were used for 
affinity precipitation. Precleared cell lysates containing 400-800 µg of protein were incu-
bated with 3-4 µg of SH2 domain conjugates for 2 h at 4° C. Precipitates were washed 
three times with PBS-Tween buffer. Precipitated proteins were eluted with 2-fold Laemmli 
sample buffer containing 20 mM dithiothreitol and 10 mM glutathione and were used for 
PAGE and Western blotting. 
2.5.11  Enzyme immunoassay (ELISA) and flow cytometry
Enzyme immunoassay for quantitative measurement of human uPA and uPAR 
in mono- and coculture cell-free fractions was performed using commercial kits from 
Monozyme (Hoersholm, Denmark) according to standard protocols from supplier. 
Single cell-associated fluorescence for uPAR (CD 87) was quantified by flow cytom-
etry with a FACScan flow cytofluorometer (Becton-Dickinson). Binding of R-phycoerythrin 
(R-PE)-conjugated mouse anti-human CD87 monoclonal antibody (PharMingen, San 
Diego,USA) to surface receptors on monocytes and VSMC was determined on freshly de-
tached, unfixed cells according to the standard protocol from antibody supplier.
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2.6  Microscopy
2.6.1  Time-Lapse Video Microscopy 
Before wounding, cells were cultured in serum-free SmGM2 medium for 6 h. In migra-
tion experiments with PI3-K inhibitors, cells were pretreated with wortmannin or LY294002 
in serum-free medium for 30 min before wounding, and then inhibitors were added again to 
the serum-free medium after wounding with or without uPA. Cell migration was monitored 
by time-lapse imaging using an endoscope (telecam PAL 20210036, Storz, Germany) 
attached to an Axioplan microscope (Zeiss) and acquisition and analysis software (Avid 
Videoshop, Avid Desktop Software Inc., Microsoft Excel). The wounds were viewed inside 
an environmental chamber under constant temperature (37° C) and humidified in 5% CO2 
and air (CTI Controller 3700; Zeiss). Microscopic recordings were started immediately 
after wounding, and then further images were taken every 30 min for 9 h following wound-
ing. Results are the mean number of migrated cells ± S.D. at indicated time points or -fold 
stimulation of at least five separate experiments. 
2.6.2 Immunofluorescence Microscopy
Cells were seeded and cultured on glass coverslips, and wounding was performed as 
indicated above. Cells were allowed to migrate for 8 h at 37°C and then treated for the dif-
ferent periods of time with appropriate inhibitors or stimulators. After incubation, cells were 
fixed with 4% paraformaldehyde in PBS for 20 min, RT, washed three times with PBS, 
and permeabilized with 0.1% Triton X-100 in PBS for 3 min, RT. Then cells were stained 
with Alexa 488-conjugated phalloidin for 20 min, RT. For staining of Tyk2, Jak1, STAT1, 
and uPAR, appropriate primary antibody against individual proteins in the concentration 
5 µg/ml was used. Cells were washed three times with PBS and incubated 1 h RT with 
appropriate Alexa 488 (or Cy3) secondary antibody in the concentration 5 µg/ml. Cells 
were washed as described above and coverslips were mounted with Vectashield mount-
ing medium. Color images were captured using a SensiCam 12-bit CCD camera (PCO 
Computer Optics, Kelheim, Germany) and acquisition and analysis software AxioVision 
and KS 300 (Carl Zeiss, Thornwood, NY, USA) running on a PC 586/200MMX-64MB 
(Inteq, Berlin, Germany). Images for Alexa 488 and Cy3 staining were captured digitally 
and were imported as TIF files into Adobe Illustrator for analysis and printing. 
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2.7 Functional Studies
2.7.1 Wound Assay
The wound assay was performed as described elsewhere (Okada et al., 1995). Briefly, 
VSMC were plated confluently on 14-mm diameter glass coverslips (Menzel-Glaser, 
Braunschweig, Germany) and were placed in 35-mm tissue culture dishes. A wound width 
of approximately 3 mm was made using a razor blade. VSMC were allowed to recover for 
4—24 h and processed as noted below.
2.7.2  Chemotaxis Assay
Chemotaxis assay was performed using modified Boyden chambers with polyvinylpyr-
rolidone-free polycarbonate filter membranes, 8-µm pore size. 30,000 cells in serum-free 
SmGM2 medium were added to the upper well of the Boyden chamber. uPA was diluted 
in serum-free SmGM2 and added to the lower well of the Boyden chamber, and migra-
tion was allowed for 4h. When chemotaxis was performed in the presence of the PI3-K 
inhibitors wortmannin or LY294002, these substances were added to the upper well. All 
experiments were performed in triplicates. Cell migration was quantified by densitometry, 
and cell migration in the absence of chemoattractant was taken as 100%.
 2.7.3 Adhesion Assay
The assay was performed in 96-well plates coated with bovine vitronectin at the con-
centration of 0.35 pg/ml at 37 °C for 1 h and then blocked with 3% BSA in PBS for 30 min. 
Wells treated with 3% BSA only served as background samples. VSMC were detached with 
5 mM EDTA inPBS, pH 7.4 and then washed once with PBS. Cells were resuspended in 
serum-free medium, plated at 1.5x104 cells/well and allowed to incubate at 37 °C for 20 min. 
Then the wells were rinsed twice with PBS containing Ca2+ and Mg2+ to remove nonadherent 
cells and then PBS without Ca2+ and Mg2+ was added together with hexoseamidasereagent (15 
mM p-nitrophenyl N-acetyl-β-D-glucosaminide, 0.5% Triton-X 100, 100 mM sodium citrate buf-
fer, pH 5.0) for 40 min at 37 °C. The reaction was stopped by adding 0.2 M NaOH containing 
5 mM EDTA and absorbance was measured at 405 nm.
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Fig. 9  Schematic overview of the adenovirus technology. 
The gene of interest is first cloned into a shuttle vector, e.g., pTGBKCMV. The resultant plasmid is 
linearized by digesting with restriction endonuclease PacI, and subsequently cotransformed into E. coli. 
BJ5183 cells with an adenoviral backbone plasmid, e.g., pHVad1. Recombinants are selected for ampicillin 
resistance, and recombination confirmed by restriction endonuclease analyses. Finally, the linearized PacI 
recombinant plasmid is transfected into adenovirus packaging cell lines, e.g., 293 cells.
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2.7.4 Proliferation Assay
DNA synthesis was measured using the 5-bromo-2-deoxy-uridine (BrdU) labeling and 
detection kit III from Roche Diagnostics (Indianapolis, IN, USA) as described by supplier.
2.8  Recombinant Adenovirus
2.8.1 Recombinant Adenovirus Construction 
A schematic overview of the production of recombinant adenovirus is shown (Fig. 
10). In the adenovirus generation system (Chartier et al., 1996), the cDNA of interest 
is cloned into either of two shuttle vectors pHV1 or pTGBKCMV. Once constructed, the 
shuttle vector is linearized with Pme I and Ehe I (can be replaced by Stu I, Not I, XcaI 
or BstEII). After restriction digestion two fragments were separated by electrophoresis in 
agarose gel. Plasmid fragment with origin replication and ampicillin resistanse gene was 
discarded. Fragments from transfer vector was cotransformed into BJ5183 together with 
pHV1, the linearized by Cla I viral DNA plasmid. Transformants are selected for ampicilin 
resistance, and recombinants are subsequently identified by restriction digestion. Once 
a recombinant is identified, it is produced in bulk using the recombination-deficient DH5α 
(Clontech), strain. Purified recombinant Ad plasmid DNA is digested with Pac I to expose 
its inverted terminal repeats (ITR), and then used to transfect HEK293 cells where de-
leted viral assembly genes are complemented in vivo.
The concentration of the recombinant adenovirus was assessed based on the absor-
bance at 260 nm and plaque assay (Stratford-Perricaudet, Makeh et al. 1992).
2.8.2 Calcium-Phosphate-Mediated Transfection of HEK 293 Cells 
Twenty-four hours before transfection, exponentially growing cells were harvested by 
trypsinization and replated at density of 8 x 105 cells in 60-mm tissue culture dishes (near 
50 % confluence) complete DMEM medium with 10% FCS. The cultures were incubated 
for 20-24 h at 37° C in a humidified incubator with an atmosphere of 5 % CO2. The me-
dium was changed 1 h before transfection.
The calcium phosphate-DNA coprecipitate was prepared as follows: Combine 25 µl 
of 2.5 M CaCl2 with of plasmid DNA (4 µg pAd digested PacI and 10 µg pUC18 as car-
rier) in a sterile 15-ml plastic tube and, if necessary, the final volume was brought to 250 
µl with sterile H2O. This 2x calcium-DNA solution was mixed with an equal volume of 2x 
Hepes Transfection Buffer “HTB” (275 mM NaCl; 28 mM Na2HPO4 x2 H2O; 10 mM KCl; 
42 mM HEPES, pH 6.75) at RT. The ingredients were quickly mixed and allowed to stand 
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for 1 min. The calcium phosphate-DNA suspension was immediately transferred into the 
medium above the cell monolayer. The plates were rocked gently to mix the medium, 
which will become yellow-orange and turbid. After 6 h incubation, the medium and DNA 
precipitate was removed by aspiration. 3 ml of warmed (37°C) complete growth medium 
with 0.8% SeaPlaque agarose (FMC Bioproducts, Rockland, ME, USA) was overlayed, 
and the cells were put into the incubator for 3 days. 3 ml complete DMEM medium was 
added to cells after 3 days. Plaques were appeared within 10-21 days. To maintain cell 
viability throughout plaque formation, additional agarose/DMEM mix was overlayed onto 
each dish every 4 to 5 days or when medium started turning yellow.
2.8.3 Purification of Recombinant Adenovirus by Double Cesium 
Chloride Gradient
Purification of an Ad was a three-step process:
1. ultracentrifugation on a discontinuous CsCl gradient which removes the majority of 
cellular contaminants and defective viral particles
2. ultracentrifugation on a continuous CsCl gradient to completely separate infectious 
from defective viral particles
3. removal of CsCl by desalting.
2.8.4 Discontinuous Gradient
HEK 293 confluent cells were transferred from the 5 x 175 cm2 flasks to the 40 x 15 
cm dishes (d0). After 3 days (d3) cells were 70-80% confluent (5x107 cells/dish). Total 
amount of cells was about 2x109. Virus (50 ml virus cell lisat) was added to 240 ml DMEM 
and redistributed to each dish in 7 ml virus solution. Cells were incubated 4-5 h 37o C, 
in 5% CO2, then 20 ml fresh DMEM with 10% FCS was added to each dish and incu-
bated 36-48 h 37o C, 5% CO2. After several days cells showed strong cyttopathic effect 
(CPE). Cells were suspended by pipetting and collected by centrifugation (20 min, 1,500 
rpm, 4o C). Ten dishes were used for the preparation of single cesium chloride gradient 
centrifugation. Cell pellet from ten dishes was resuspended in 5 ml DMEM medium with 
10% FCS and was extracted viral particles by performing three freeze/thaw cycles at -
20°C/37°C. Cell debris were removed by centrifugation (15 min 5,500 rpm, 4oC). 2 ml of 
CsCl ρ1.5 (10 mM Tris-HCl, pH 7.9) were slowly poured into polyallomer tubes with a 2 
ml pipette. Very gently, with 2 ml of CsCl ρ1.35 (10 mM Tris-HCl pH 7.9) and 1 ml CsCl 
ρ1,25 (10 mM Tris-HCl pH 7.9) were overlayed. On the top of each discontinuous gradient 
up to 7 ml of viral particle stock in DMEM 10% was loaded. The tubes were centrifuged at 
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100,000 x g (35,000 rpm in SW 40 rotor, Beckman Instruments, Palo Alto, CA) for 2 h at 
10° C, deceleration rate = 0. In a laminar flow hood, the tubes from the rotor were carefully 
removed. Using a 10 ml pipette, most of the impurities from the top of the gradient were 
aspirated. Using a 1 ml syringe with an 18G needle the viral band (about 1 ml) was aspi-
rated, avoiding collecting other bands and impurities. The solution containing the viruses 
was transferred the to a sterile 15 ml polypropylene tube and mixed with 11 ml CsCl ρ1,35 
(10 mM Tris-HCl pH 7.9).
2.8.5 Continuous Gradient
The 11-12 ml diluted viral suspension was loaded in 12 ml polyalomer tubes and 
centrifuged at 100,000 x g (35,000 rpm with SW 40 rotor) at 4° C for 20 h (deceleration 
rate=0). Using a 10 ml pipette, most of the gradient and impurities were removed from 
the top of the tube while avoiding the lowest (bottom) bluish white band containing the 
viruses. The lowest (bottom) bluish white band containing the viruses was collected using 
syringe with 20G needle.
2.8.6 Virus Desalting and Concentration by Pharmacia NAP-25 
Column
Cesium chloride was removed by gel filtration. The Pharmacia NAP-25 column 
(Amersham Pharmacia Biotech, Piscataway, NJ) was equilibrated the approximately 15 
ml of the “Ad” buffer (10 mM Tris-HCl, pH 8.0; 135 mM NaCl; 3 mM KCl; 1 mM MgCl2; 10 
% (v/v) glycerol). The sample was mixed with “Ad” buffer for final volume 2,5 ml and put 
onto the column in a maximum volume of 2,5 ml. The buffer was allowed to enter the gel 
completely. The bad column volume (near 1,5 ml) was discard. Fractions containing ad-
enovirus were collected. Additional 2 ml “Ad” buffer was added in column to completely 
elute adenovirus. The desalted virus was kept at -80°C for long-term storage. A small 
aliquot was kept separately to determine the stock titer with the remainder aliquoted in 
convenient volumes for use in upcoming experiments.
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3  Results
3.1 Urokinase Stimulates Human Vascular Smooth Muscle Cell Migration 
via Phosphatidylinositol 3-Kinase —Tyk2 Interaction
uPA/uPAR system is known to be involved in tissue remodeling and wound healing by 
affecting cell migration, adhesion and proliferation (Ossowski and Aguirre-Ghiso, 2000), 
most likely via induction of intracellular signaling. One of the major uPA/uPAR-related 
signaling cascades in human VSMC is the Jak/STAT pathway, however, the molecular 
mechanisms underlying the interplay between Jak/STAT signaling and uPA-directed 
VSMC migration remains unexplored.
3.1.1 Jak1 and Tyk2 are Polarized with uPAR to the Leading Edge of 
Migrating VSMC
To explore the proposed interplay between the uPA/uPAR system and the Jak/STAT 
pathway upon cell migration, we used a migration wound assay.  VSMC migration in 
one general direction following wounding was observed by 4 h after injury and was pro-
nounced at 24 h (Fig.  10). In confluent VSMC, uPAR was distributed over the body of the 
cell in a punctate pattern, with some increased staining at the periphery. However, the 
staining was not restricted to a specific site on the cell membrane (Fig. 10). In response 
to injury, about 25% of migrating cells demonstrated a highly asymmetric distribution of 
uPAR to the leading edge (Fig. 10).
 To obtain evidence that Jaks might be associated with uPAR within the same signaling 
complex upon cell migration, double immunolabeling experiments were performed using 
anti-uPAR mAb and pAb to individual kinases. Antibodies to Jak2 and Jak3 demonstrated 
a homogeneous punctate staining pattern (data not shown), with increased staining at the 
sites of cell-cell contacts. However, the staining was not restricted to the leading edge of 
the cells either in wounded and non-wounded culture. In contrast, strongly pronounced 
polarization of Jak1 and Tyk2 to the leading edge of migrating cells and colocalization with 
polarized uPAR could be seen already 6 h after wounding. Control antibodies showed no 
staining above background autofluorescence (data not shown). 
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3.1.2 Tyk2 and PI3-K are Associated
To examine the potential link between uPA/uPAR-directed Jaks and PI3-K, we first 
performed immunoprecipitation with anti-Jak antibodies and looked for the p85 subunit 
of PI3-K in the immunoprecipitates. Proteins that were coprecipitated with Jaks were 
subjected to in vitro kinase assay, and the phosphorylated proteins were reimmunopre-
cipitated with anti-p85 antibody. As a control for p85 recovery, both rounds of immuno-
precipitation were performed with anti-p85 antibody. As shown in (Fig.  11), upper panel, 
one band corresponding to p85 was detected in Tyk2, but not in Jak1, Jak2, or Jak3 
20 µM 
A
C'B'A'
CB
Fig. 10  Polarized distribution of uPAR, Jak1 and Tyk2 in the wounded VSMC cultures.
Wounded cultures with directionally migrating cells were stained 18 h after wounding with antibodies to 
the following proteins: uPAR (A,A’) in green, Jak1 (B) in red, and Tyk2 (B’) in red. In the third column (C,C’) 
are superimposed composite figures of either Jak1 and uPAR or Tyk2 and uPAR from the first and second 
columns. Yellow color denotes the colocalization of two proteins. Bar 20 µm. In each panel, arrows indicate 
the direction of the wound.
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immunoprecipitates. The identity of the immunoprecipitated p85 band was confirmed by 
immunoblotting with anti-p85 antibody (Fig. 11, lower panel). To verify that antibodies to 
Jak1, Jak2, and Jak3 were behaving appropriately under our experimental conditions, 
the additional positive controls were performed, confirming that all three kinases might 
be precipitated from the VSMC lysates (Fig. 11 B). These data demonstrate that p85 can 
directly and constitutively associate with Tyk2 in VSMC. 
Fig.11  Tyk2 and PI3-K are associated in VSMC.
A, proteins co-precipitated (IP) with antibodies (Ab) to Jak1, Jak2, Jak3, or Tyk2 were subjected to in vi-
tro kinase assay and reimmunoprecipitated (re-IP) with anti-p85 antibody (upper panel). The left lane shows 
the results of the in vitro kinase assay combined with two rounds of immunoprecipitation with anti-p85 
antibody as control for p85 recovery. Phosphorylated proteins were subjected to SDS-PAGE and autoradi-
ography. The identity of the immunoprecipitated p85 band was confirmed by immunoblotting with anti-p85 
antibody (lower panel). B, Janus kinases were immunoprecipitated from VSMC lysates under the same con-
ditions as used in A and were identified by immunoblotting as indicated. C, PI3-K activity was measured in 
Tyk2 immunoprecipitates of unstimulated (control) or uPA-stimulated (uPA) VSMC (upper panel). Products 
of PI3-K were separated by thin layer chromatography and visualized by autoradiography. The lower panel 
shows the results of densitometric quantification. WB, Western blot.
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Fig.  12  uPA induces PI3-K activation and tyrosine phosphorylation of p85 in VSMC. 
A, VSMC were treated with 1 nM uPA for the indicated times at 37 °C, and the PI3-K assay was per-
formed with subsequent thin layer chromatography and autoradiography visualizing phosphatidylinositol 
1,4,5-trisphosphate (PtdIns(3)P) products. B, cells were untreated or treated with uPA for 30 min and/or with 
wortmannin, as indicated. C, VSMC were stimulated with 1 nM ATF for 45 min in the presence or absence 
of 20 nM soluble recombinant uPAR. Quantification of the results by densitometry is shown below each 
panel. D, phosphorylation of p85 was assayed in control VSMC and after cell activation with 1 nM uPA by in 
vitro kinase assay combined with two rounds of immunoprecipitation (IP and re-IP) with anti-p85 polyclonal 
antibody (Ab). Phosphorylated proteins were subjected to SDS-PAGE and autoradiography before (upper 
panel) and after (middle panel) KOH treatment. The equal loading of precipitated proteins on the gel was 
confirmed by immunoblotting (lower panel).
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3.1.3    uPA Induces PI3-K Activation and Tyrosine Phosphorylation 
of p85
To address the potential role of PI3-K in the uPA-mediated signaling, we assayed 
PI3-K activity directly by measuring the levels of the product, phosphatidylinositol phos-
phate, in serum-starved VSMC stimulated with uPA at different time points. As shown in 
(Fig.    12) uPA induced a significant increase (up to 3-fold) in PI3-K activity in a time-de-
pendent manner with a sustained PI3-K activation observed after 3 h. The PI3-K-specific 
inhibitor wortmannin, which binds covalently to the catalytic p110 subunit of PI3-K and 
inhibits PI3-K irreversibly, at nanomolar concentrations completely blocked the uPA-in-
duced stimulation of enzyme activity (Fig. 12). To assess a potential contribution of uPA’s 
proteolytic activity to the mechanisms of PI3-K activation, the amino-terminal fragment of 
uPA, ATF, was used for cell stimulation. ATF provided the same effect (Fig. 12), confirming 
the involvement of proteolytically inactive uPA in signaling events. We also examined the 
requirement for uPAR upon PI3-K activation. For this purpose, we used soluble recom-
binant uPAR, which is a known competitor for the uPA- and ATF-uPAR binding. The data 
presented in Fig. 12 clearly demonstrate that the pretreatment of VSMC with soluble re-
combinant uPAR significantly decreased the uPA/ATF-induced PI3-K stimulation (shown 
for ATF).
We next examined PI3-K p85 subunit phosphorylation after uPA stimulation using 
an in vitro kinase assay combined with two rounds of immunoprecipitation with anti-p85 
antibody (Fig.12, upper panel). The results demonstrate that uPA markedly increased 
phosphorylation of the p85 protein. The band was resistant to alkaline hydrolysis, indi-
cating tyrosine phosphorylation (Fig.12, middle panel). The equal loading of precipitated 
material on the gel was confirmed by immunoblotting (Fig. 12, lower panel).
3.2.1 Overexpression of Wild Type Tyk2 and Mutant Forms Tyk2 in 
VSMC
To further analyse the revealed interaction between Tyk2 and PI3-K, we overex-
pressed wild type Tyk2 in VSMC. The overexpression enabled us to obtain cell lysates 
enriched in Tyk2, which is otherwise expressed at a low level in native VSMC. Primary 
cultured smooth muscle cells from different origins display a strongly toxic reaction in re-
sponse to transfection by commercially availably transfection reagents (such as FuGene, 
Lipofectamine) (Nabel et al., 1991; Keogh et al., 1997). To overcome these difficulties, we 
generate adenovirus constructs that can be effectively used for infection of VSMC and 
overexpression in these cells of wild and mutant forms of Tyk2.
To obtain full-length cDNA copy for Tyk2, a long PCR protocol was used.  For am-
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plification, cDNA samples were prepared by reverse transcription reaction on mRNA 
isolated from primary culture of human VSMC. After amplification, cDNA was subjected 
to electrophoresis in 1% agarose gel, recovered from gel, cloned in pBluescriptII SK+ 
and sequenced. The results confirmed structure for full length Tyk2. Mutant form of Tyk2 
(Ad5Tyk2KE) was obtained by site-directed mutagenesis in the catalytic active center 
of the kinase domain Lysine 930 was replaced by glutamine (AAG->GAG)  (Fig. 13) . 
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FIG. 14 Adenoviral-mediated overexpression of β-lactosidase enzyme in VSMC.
The cells were infected with replication-defective adenovirus expressing β-galactosidase at a multiplic-
ity of infection of 0 (panel A), 50 (panel B) and 250 (panel C) viral particles/cell (moi). More than 95% of the 
cells expressed the transgene after 48 h. Cells were photographed under phase contrast microscopy in a 
light field.
Fig. 13  Structures of mutant forms of the Janus kinase Tyk2.
A, Point mutation in kinase domain of the Tyk2-kinase deficient form. B, Deletion in carboxyl terminus 
completely abrogates kinase activity of Tyk2.
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Fig. 15 Overexpression of Tyk2 in VSMC.
VSMC were infected with Ad5Tyk2, and 
immunofluorescent staining for Tyk2 was 
performed in noninfected cells (lower image) 
and Ad5Tyk2-VSMC (upper image) using 
anti-Tyk2 monoclonal antibody (Ab) and 
corresponding Cy3-conjugated secondary 
antibody.
�� ��� ����
�
����
����
��������
����
��������� �����
����������
������������
����
����
��������
����
�������� ���������������
������������
���
Fig. 16 Time-dependent expression of 
Tyk2 in adenovirus-infected VSMC.
Northern (upper panel) and Western 
(lower panel) blot (WE) time course anal-
ysis of Tyk2 mRNA and protein expres-
sion in adenovirus-infected VSMC. 
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Mutation of this site has been shown to abrogate the kinase activity of Tyk2 (Colamonici 
et al., 1994). One more kinase-deficient construct (Tyk2∆C) was generated by remov-
ing kinase domain after 776 aa Fig. 13. As a control virus, adenovirus-expressed β-ga-
lactosidase (AdβGal) was used. This virus was used to establish and optimize infection 
protocol (Fig. 14).  The optimal infection was found to correspond 250 pfu/cell and was 
correspondingly used in our experiments.
Adenoviruses for expression of wild and mutant forms Tyk2 were generated as de-
scribed in method section. After purification of recombinant adenoviruses, their activity 
was determined 1-3*1011 pfu/ml by titration assay.
� �
� �
Fig. 17  Functional validation of Tyk2 constructs.
A-C: VSMC were stimulated with interferon-α (IFNα) for 30 min, fixed and stained with anti-STAT1 mono-
clonal antibody and corresponding Cy3-conjugated secondary antibody.
A, non-infected cells; B, AdTyk2KE-infected cells; C, AdTyk2∆C-infected cells; D, non-stimulated cells.
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Immunocytochemical study of control uninfected cells and Ad5Tyk2-VSMC using anti-
Tyk2 antibody confirmed the efficiency of cell infection with the recombinant adenovirus 
under these conditions Fig. 15 . Northern and Western blot analysis were further used to 
confirm the expression of Tyk2 mRNA and protein in VSMC infected with adenovirus and 
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Fig. 18  Overexpression of Tyk2 dominant-negative forms inhibits STAT1 phosphorylation. 
Protein extracts from VSMC were analyzed by Western blot to detect expression and phosphorylation of 
STAT1 using anti-STAT1, anti- phosphoserine STAT1 (Ser 727 P site) and anti- phosphotyrosine (Tyr 702 P 
site) STAT1 monoclonal antibodies, respectively. Cells were also infected with a control virus β-LacZ. STAT1  
phosphorylation levels were evaluated by Western blot analysis. The cells infected with a control virus, wild 
type Tyk2 expressed adenovirus (AdTyk2wt), defected in kinase domain Tyk2 adenovirus (AdTyk2KE) and 
kinase domain truncated form Tyk2 (AdTyk2∆C) were stimulated with or without 1 ng/ml interferon-α (INFα) 
or interferon-γ (INFγ) for 30 min.
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cultured for different time periods. As shown in Fig.16, VSMC infection with Ad5Tyk2 re-
sulted in a dramatic increase in Tyk2 mRNA and protein levels relative to uninfected cells. 
The Tyk2 protein expression reached a maximum 2 days after infection and decreased 
within the next 3 days. In further experiments, we therefore used VSMC cultured for 2 
days after infection with Ad5Tyk2.
3.2.2 Overexpression of Mutant Forms Tyk2 Leads to Inhibition of 
Endogenous Tyk2 Kinase Activity 
Up to date there is no convenient direct method to measure the kinase activities of 
Jaks. Therefore an indirect method was used, namely phosphorylation of STAT proteins 
that serve as substrates for Jaks. VSMC were infected with control virus or with virus con-
structs of Tyk2 mutant forms (Ad5Tyk2KE; Ad5Tyk2∆C). IFN-γ was used as a strong posi-
tive control for the Jak/STAT activation (Shuai et al., 1993) Cells were treated with 1000 
U/ml IFN-α or IFN-γ at 30 min or left untreated as indicated and used for immunoblotting 
with anti-STAT1 phosphotyrosine  701 or anti-STAT1 phosphoserine 727 antibodies. To 
control Tyk2 expression, reprobing with anti-Tyk antibody was used. As shown in Fig. 18, 
overexpression of truncated forms of Tyk2 reduced IFN-γ - induced STAT1 phosphoryla-
tion on Ser727 and Tyr701.
In order to confirm dominant negative properties of mutant form, VSMC expressing 
transgenes were activated by IFN-γ. In response to IFN-γ, activated and phosphorylated 
STAT1 normally undergoes translocation to cell nucleus (Fig.17, control VSMC). In con-
trast, STAT1 nuclear translocation was blocked in VSMC overexpressing mutant forms of 
Tyk2 (Fig. 17) These data confirm the dominant negative expression of Ad5Tyk2KE and 
Ad5Tyk2∆C leading to inhibition of endogenous Tyk2 kinase activity (Fig. 18).
3.2.3 Tyk2 and PI3-K Directly Interact via SH2 Domains of PI3-K
To investigate the interaction mechanisms between Tyk2 and p85, in vitro binding ex-
periments were performed. We used two GST fusion proteins containing the single C- and 
N-terminal Src homology 2 (SH2) domains of the human p85 subunit of PI3-K (GST-p85-
C-SH2 and GST-p85-N-SH2) immobilized on the glutathione-agarose beads. The beads 
were incubated with the lysates of unstimulated and uPA-stimulated Ad5Tyk2-VSMC, and 
the precipitated proteins were analyzed by immunoblotting with anti-Tyk2 antibody. As 
shown in Fig. 19, one major band corresponding to Tyk2 was detected in both GST-p85-
C-SH2 and GST-p85-N-SH2 precipitates from uPA-stimu-lated cells. Tyk2 bands identified 
in unstimulated cells were significantly weaker. These results strongly suggest that Tyk2 
directly associates with PI3-K through the binding to both C-and N-terminal SH2 domains 
of p85 and that this association is uPA-inducible.
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3.2.4 PI3-K and Tyk2 Are Required for the uPA-induced VSMC 
Migration
Recent reports imply that PI3-K is involved in cell migration control (Adam et al., 
1998; Reiske et al., 1999; Vanhaesebroeck and Waterfield, 1999). Although uPA is known 
to regulate cell migration, the underlying molecular mechanisms are unclear. Therefore, 
we next examined the possible impact of PI3-K on VSMC migration in response to uPA. 
For this purpose, two main approaches were used, namely directional VSMC migration 
in Boyden chambers and cell movement in a wounded VSMC monolayer monitored by 
time-lapse imaging. Fig. 20 A displays the data on directional migration of VSMC along 
the uPA gradient tested in a microchemotaxis Boyden chamber. After 4 h, cell migration 
in response to uPA was significantly enhanced about 3-fold, compared with migration in 
the presence of medium alone. To examine the requirement of PI3-K for uPA-promoted 
cell migration, VSMC were subjected to migration assays in the presence of two unrelated 
structurally distinct specific PI3-K inhibitors, wortmannin and LY294002. Cell treatment 
with both inhibitors decreased uPA-related cell migration with no statistically significant 
effect on the basal migration (Fig. 20).
To further characterize VSMC migration, an in vitro injury assay was performed. This 
cell migration model was used to assess the potential effects of constant uPA doses and 
to analyze the role of PI3-K in this process. The cell migration rate was calculated from 
the cell number migrating into the wounded area within 9 h after wounding. In these ex-
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Fig.19  Tyk2 and PI3-K regulatory sub-
unit are directly associated.
Cell lysates from uPA-stimulated and 
control Ad5Tyk2-VSMC were subjected 
to affinity precipitation (AP) with GST-
p85-C-SH2 (upper panel) or GST-p85-N-
SH2 (lower panel). Precipitated proteins 
were separated by 7.5% SDS-PAGE and 
analyzed by immunoblotting with anti-Tyk2 
monoclonal antibody.
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Fig.  20   PI3-K is required for the VSMC migration in response to uPA.
A, VSMC were serum-starved for 24 h and then subjected to chemotaxis assay using a modified Boyden 
chamber. Cells were resuspended in serum-free medium alone or in serum-free medium containing 200 
nM wortmannin or 50 mM LY294002, as indicated, and were then left to migrate toward serum-free medium 
alone or 100 nM uPA. Random cell migration toward medium alone without any chemoattractant was con-
sidered as 100% migration.
B, VSMC were wounded, and cell migration was evaluated using time lapse videomicroscopy for non-
treated cells, after pretreatment of cells with 200 nM wortmannin or 50 mM LY294002 and in the presence 
of 50 nM uPA as indicated. Results of cell migration are shown as numbers of migrated cells at the indicated 
time points ± S.D. of n= 10 (control), n = 9 (uPA), n=6 (wortmannin (wortm.)), n= 7 (wortmannin + uPA), 
n= 5 (LY294002), and n= 8 (LY294002 + uPA). *,p < 0.02 uPA versus the control; **,p < 0.006 uPA versus 
wortmannin + uPA, uPA versus LY294002 + uPA (unpaired t test).
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Fig. 21  Tyk2 is required for the uPA-induced PI3-K activation and VSMC migration.
A, VSMC were infected with Ad5Tyk2KE, and immunofluorescent staining for Tyk2 was performed in 
noninfected cells (right image) and Ad5Tyk2KE-VSMC (left image).  B, Northern (upper panel) and Western 
(lower panel) blot (WE) time course analysis of Tyk2KE mRNA and protein expression in adenovirus-in-
fected VSMC. C, VSMC expressing Tyk2 wild type or mutant form were stimulated with 1 nM uPA for 45 
min, and the PI3-K assay was performed with subsequent thin layer chromatography and autoradiography 
of phosphatidylinositol 1,4,5-trisphosphate (PtdIns(3)P) products (upper panel) and their quantification by 
densitometry (lower panel). D, VSMC expressing Tyk2 wild type or mutant form were wounded, and cell 
migration was evaluated using time lapse videomicroscopy as indicated above. Results of cell migration 
are shown as -fold stimulation ± S.D. of n= 5 (Ad5Tyk2-VSMC, control), n = 6 (Ad5Tyk2-VSMC, uPA), n= 7 
(Ad5Tyk2KE-VSMC, control), or n = 5 (Ad5Tyk2KE-VSMC, uPA). n.s., uPA nonsignificant versus the control; 
***,p < 0,0003 uPA versus control.
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periments, VSMC migration significantly increased in the presence of uPA compared with 
migration with medium alone as early as 2 h after wounding (Fig. 20 B). Furthermore, 
VSMC treatment with either wortmannin or LY294002 completely abolished the effects of 
uPA. Thus, regulation of cell migration by uPA is PI3-K-dependent.
The next series of experiments were performed to determine whether Tyk2 is required 
for PI3-K-mediated VSMC migration in response to uPA. VSMC were adenovirally infected 
to express the dominant negative form of Tyk2 devoid of kinase activity, as described 
above. The efficiency of cell infection was confirmed by immunostaining, Northern and 
Western blotting (Fig. 21, A and B). As shown in Fig. C, uPA-induced PI3-K activation was 
blocked in Ad5Tyk2KE-expressing cells, whereas in wild type Ad5Tyk2-expressing VSMC, 
PI3-K activity increased after uPA stimulation. These results demonstrate that Tyk2 is re-
quired for the uPA-related PI3-K activation and that Tyk2 functions presumably upstream 
of PI3-K in VSMC.
To elucidate whether Ad5Tyk2KE mutant also inhibits PI3-K-mediated VSMC migra-
tion in response to uPA, cell migration assays were performed using the wounding model, 
as described above. As shown in Fig. 21 D , VSMC expressing wild type Tyk2 demon-
strated an approximately 2-fold increase in cellular migration in the presence of uPA. By 
contrast, uPA did not affect cell migration in Ad5Tyk2KE-expressing VSMC.
3.2.5 Association of Tyk2 and PI3-K Is Essential for uPA-related 
Cytoskeletal Reorganization in Migrating VSMC
Cell motility is generally associated with polarization of initially unpolarized cells. An 
active leading edge facing the cell-free area is formed. In addition, focal contacts, stress 
fibers, and actin filaments are rearranged (Lauffenburger and Horwitz, 1996). To examine 
the cytoskeletal reorganization resulting from uPA-induced activation of Tyk2 and PI3-K in 
migrating VSMC in the wounding model, we again performed time-lapse video microsco-
py and immunofluorescent staining with Alexa 488-conjugated phalloidin. As reported by 
others (Degryse et al., 1999) and as shown in Fig.  22, VSMC migrating in the presence of 
uPA developed a polarized morphology, with extended lamellipodia extrusions at the lead-
ing edge facing the open space (Fig. 22 ). Formation of actin-rich lamellipodial extensions 
at the leading edge and abundant stress fibers in response to uPA was observed also 
in VSMC expressing wild type Tyk2 (Fig. 22). The dynamic cytoskeletal activity of both 
cell types migrating without uPA was significantly weaker (Fig. 22 control ). By contrast, 
lamellipodial activity was completely different in VSMC expressing a Tyk2 mutant form. 
Ad5Tyk2KE-VSMC did not display a strong morphological polarity with clear leading edge 
and revealed in the presence of uPA mainly small lateral protrusions localized at the sides 
and not at the leading edge of migrating cells (Fig.  22 ).
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To examine the contribution of PI3-K to the observed cytoskeletal rearrangements, 
cells were treated with PI3-K inhibitors. VSMC treatment with wortmannin caused a com-
plete loss of uPA-induced polarity Fig.  22. In Ad5Tyk2-VSMC treated with wortmannin, 
cell polarity was also disturbed; the protrusive leading edge, clearly developed in the pres-
ence of uPA and absence of wortmannin, was damaged Fig. 22. These cells came to be 
similar to Ad5Tyk2KE-VSMC, whose uPA-induced lamellipodial activity can be seen all 
around the cells’ periphery (Fig.  22). Moreover, wortmannin treatment of VSMC express-
ing wild type and the mutant form of Tyk2 resulted in the reorganization of stress fibers. 
�� ��
�
�
�
� �
�
�
� �
�
�
�
������������ ���� ������������ ��������� �����
�������
���
���� �
���� �
� ���
Fig.22 Tyk2 and PI3-K are required for the uPA-induced cytoskeletal reorganization in migrating VSMC.
 Noninfected VSMC (left column) or VSMC expressing Tyk2 wild type (middle column) or negative form 
(right column) migrated within 20 h after wounding were left unstimulated or were stimulated with 50 nM 
uPA without or with pretreatment with 100 nM wortmannin (wortm.) as indicated. The cells were then fixed 
and immunofluorescently stained with Alexa 488-conjugated phalloidin. Results are representative of 3—5 
separate experiments.
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Interestingly, these effects were especially pronounced in the presence of uPA. As can be 
seen in Fig. 22, uPA stimulation of wortmannin-pretreated VSMC resulted in disassembly 
of stress fibers, which lost organization into typical long bundles of parallel or radially di-
rected stress fibers.
Our findings demonstrate that in migrating VSMC Tyk2 is polarized to the leading 
edge (Fig.  23). The strong polarity in Tyk2 intracellular redistribution was also observed in 
migrating VSMC expressing wild type Tyk2 (Fig.  23 A,B). By contrast, in VSMC express-
ing the Tyk2 mutant form (C,D), Tyk2 was randomly distributed within the cell that might 
explain the loss of cytoskeletal polarity of these cells (Fig.  23 ).
3.3  VSMC Migration is Stimulated by Endogenous, Monocyte-Expressed 
uPA in Coculture Model
Although uPA is well-proved migratory signal for different cell types, its most biological 
activities have been studied in the above documented experiments and in the studies of 
others using exogenous recombinant or purified protein or peptides (Fazioli et al., 1997; 
Mukhina et al., 2000; Ossowski and Aguirre-Ghiso, 2000). The aim of this part of the study 
was to get evidence that VSMC migration might be regulated by endogenous uPA. We 
Fig.  23  Redistribution of Tyk2 in migrating VSMC.
Redistribution of Tyk2 is essential for the leading edge formation in migrating VSMC. VSMC expressing 
Tyk2 wild type (A, B) or negative form (C, D) migrated within 20 h after wounding and were left unstimu-
lated or were stimulated with 50 nM uPA. The cells were then fixed and stained with anti-Tyk2 monoclonal 
antibody and corresponding Cy3-conjugated secondary antibody (A, C) or with Alexa 488-conjugated 
phalloidin (B, D).
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addressed a coculture model of VSMC with peripheral blood-derived monocytes, as far 
as uPA expressed by monocytes is a potent chemotactic factor for VSMC and might serve 
for the acceleration of vascular remodeling.
3.3.1 uPA/uPAR Expression in Coculture Model
VSMC were grown in a filter separated coculture with freshly isolated peripheral 
blood-derived monocytes for 1, 2, 3 or 4 days, and then the amount of uPA secreted upon 
cocultivation in cell-free fractions was measured by means of the quantitative ELISA. The 
results shown in Fig.  24 demonstrate the fivefold increase in the uPA production during 
cocultivation. The expression of uPAR on monocytes was not changed upon cocultiva-
tion (Fig. 24), whereas expression of the cell surface uPAR in VSMC was increased on 
day two, as measured by flow cytometric analysis (Fig.  24).  To check definitely for the 
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Fig. 24  uPA and uPAR expression in cocultured monocytes and VSMC.
A, Enzyme immunoassay (ELISA) for quantitative measurement of human uPA in mono- and coculture 
cell-free fractions. 
B, Single cell-associated fluorescence for uPAR (CD 87) was quantified by flow cytometry with a FACScan 
flow cytometers to surface receptors on VSMC was determined on freshly detached, unfixed cells. Results 
are shown as folds of mean fluorescence of respectively monocultured cells (control).
C, D, RT-PCR analysis for uPA (C) and uPAR (D) mRNAs in monocytes and VSMC in coculture was 
performed using the TaqMan® method.
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probable source of the increased uPA expression in coculture, RT-PCR was performed 
separately in cocultivated VSMC and in monocytes.  As shown in Fig. 24, monocytes 
cocultivated with VSMC display strong upregulation of the uPA expression.  At the same 
time, VSMC revealed no quantitative difference in the uPA expression profile upon cocul-
tivation with monocytes (Fig.  25). The results of RT-PCR analysis of uPAR expression in 
both cell types (Fig.  24) are consistent with the above shown data obtained by flow cy-
tometric analysis (Fig. 24). Thus, uPAR was highly expressed in VSMC cocultivated with 
monocytes whereas its expression in monocytes was not changed.
3.3.2 Monocyte-Expressed uPA Stimulates VSMC Migration
To study the functional properties of VSMC upon cocultivation with monocytes, VSMC 
grown in a filter separated coculture with monocytes for 1, 2, 3 or 4 days were used for mi-
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Fig. 26 Monocytes affect VSMC functional behavior.
A, VSMC were monocultured or cocultured with monocytes for indicated times and then subjected to chemo-
taxis assay. The assay was performed using modified Boyden chambers and migration was allowed for indicated 
times. Results are mean values±SD of one representative experiment performed in triplicates.
B, VSMC were mono- or cocultured with monocytes for indicated times and then subjected to adhesion as-
say. All experiments were performed in triplicates. Results are given as mean values±SD of one representative 
experiment performed in triplicate.
C, VSMC were cocultured with monocytes as indicated above, and DNA synthesis was measured using the 
5-bromo-2-deoxy-uridine (BrdU) labeling and detection kit III. Experiments  were performed in triplicate.
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Fig. 25 RT-PCR analysis for uPA in 
VSMC.
RT-PCR analysis for uPA mRNAs of 
VSMC in coculture was performed using 
the TaqMan method.
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gration, adhesion and proliferation assays. As shown in Fig. 26, cocultivation of both cell 
types resulted in the two- to threefold increase in VSMC migration in a time-dependent 
fashion. In contrast, VSMC adhesion was decreased in a similar time-dependent manner 
(Fig. 26 ).  These observations imply endogenous signal that decreased VSMC adhesive 
capacity and served for promotion of cell motility. The observed inhibition of VSMC adhe-
sion reflects their reduced cell-cell or cell-matrix adhesive properties in coculture con-
tributing to facilitation of migration process. To investigate whether proliferation of VSMC 
might be also affected by cocultivation with monocytes, DNA synthesis in VSMC was 
measured (Fig. 26).  No changes in cell proliferation were found suggesting that coculture 
does not provide mitogenic signals utilized by VSMC. These data are also in agreement 
with the report of others where no stimulatory effect of monocytes on smooth muscle cell 
growth was found (Proudfoot et al., 1999).
In the next experimental settings we observed, that changes in VSMC migration 
monitored by time-lapse video microscopy in a direct coculture was equivalent to, but not 
additive with, the maximal effect achieved in VSMC monoculture stimulated with uPA (Fig. 
27). Moreover, the increase in cell motility was completely abolished in both cases after 
addition to mono- and coculture of the soluble uPAR (suPAR) served as a competitor for 
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Fig.  27 Increased VSMC migration in coculture is related to the uPA/uPAR system. 
Wounded monocultured or cocultured VSMC were stimulated with 50 nM uPA and pretreated with 40 nM 
suPAR, as indicated. Cell migration was monitored by time-lapse imaging. Results are the mean number of 
migrated cells at indicated time-points±SD of five (VSMC monoculture) or six (VSMC-monocyte coculture) 
experiments. **, p<0.0095 coculture versus monoculture; ***, p<0.0009  uPA versus control; **, p<0.001 
coculture + suPAR versus monoculture + suPAR; *, p<0.04 coculture versus coculture + suPAR (unpaired 
f-test).
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the uPA binding (Fig.  27). These data provide evidence that the observed effects of in-
creased VSMC migration in coculture might be induced by the upregulated expression of 
uPA by monocytes in coculture. 
66
Discussion
4  Discussion
4.1 uPA-directed Signaling in Cell Migration
In this study, evidence is provided that implies novel roles for the Janus kinase Tyk2 
and PI3-K in human coronary VSMC. As the main finding of this work, a direct association 
of Tyk2 with PI3-K through the Scr homology 2 domains of p85 subunit is demonstrated. 
These data show that Tyk2, in addition to known regulation of cell transcription via STAT 
proteins, is required for PI3-K activation thereby providing a crucial link between two 
signaling pathways. Importantly, the revealed Tyk2 and PI3-K association within the cell 
and their activation were urokinase-responsive and were required for the uPA-related 
VSMC migration. This observation is the first demonstration that PI3-K is essential for at 
least some of the uPA/uPAR functions in VSMC and that Tyk2 is the main uPA-dependent 
pathway of PI3-K activation. The functional role of endogenous uPA for VSMC migration 
was studied in coculture model, as far as uPA expressed by monocytes is a potent che-
motactic factor for VSMC and might serve for the acceleration of vascular remodeling. 
This study demonstrates that coculture of human VSMC with freshly isolated peripheral 
blood-derived human monocytes results in significant VSMC migration and cell prolifera-
tion arrest. Evidence is provided that these changes in VSMC functional behavior were 
induced by the monocyte-expressed uPA. 
VSMC proliferation and migration into the intima after vascular injury, as well as their 
formation of neointima, contribute to vessel narrowing and are pivotal to the atheroscle-
rotic process (Ross 1993). uPA and uPAR are active participants in these processes by 
regulating wound healing, tissue remodeling, and immune responses (Blasi 1999). In 
addition to the effects mediated by proteolysis, uPA and uPAR also display biological 
functions that are not directly attributable to the formation of plasmin but rather to the 
induction of cell migration and proliferation control (Dear and Medcalf 1998). The link 
between uPA/uPAR and cell motility was established over a decade ago (Gudewicz and 
Gilboa 1987; Fibbi et al., 1988; Del Rosso et al., 1993). Current data confirm the uPA-
dependent cell migration in a wide variety of cell types (Odekon et al., 1992; Busso et al., 
1994; Fazioli et al., 1997; Nguyen et al., 1998; Chiaradonna et al., 1999; Nguyen et al., 
1999; Webb et al., 2000). Nevertheless, the proposed molecular mechanisms have been 
conflicting. The uPA/uPAR-related migratory responses seem to be highly cell specific, 
implying some structural specificity and diversity of underlying signaling events. Thus, in 
human breast cancer cells MCF-7 and HT 1080 fibrosacroma cells, uPA-initiated cellular 
motility required activation of signaling cascade including Ras, mitogen-activated protein 
kinase kinase, extracellular signal-regulated kinase, and myosin light chain kinase as 
downstream effectors (Nguyen et al., 1998; Nguyen et al., 1999). On the contrary, mi-
67
Discussion
gration of human epithelial cells seemed to involve the uPA-activated protein kinase C 
(Busso et al., 1994), whereas in cells of monocytic lineage these effects were attributed 
to the activation of protein tyrosine kinases of the Src family (Resnati et al., 1996; Fazioli 
et al., 1997). In addition, uPA/uPAR-related cell migration is integrin-dependent (Carriero 
et al., 1999; Yebra et al., 1999).
The molecular machinery of uPA/uPAR-related VSMC migration remains sparsely 
explored, although the recent generation of transgenic mice deficient in uPA and uPAR 
demonstrated that VSMC migration is dependent on the fibrinolytic system and is decisive 
for the severity of vascular damage (Carmeliet et al., 1997; Carmeliet and Collen 1998). 
Separate recent findings confirm migration of rat VSMC initiated by uPA/uPAR binding 
and suggest involvement of Src tyrosine kinase and G protein in this process (Degryse 
et al., 1999). We suggested a role for the Janus kinases in VSMC migration and showed 
that Jakl and Tyk2 were co-localized with the uPAR to the leading edge of migrating VSMC 
(Dumler et al., 1998). However, to generate migratory responses, Jaks were expected 
to signal independently of STAT activation most likely through a link to an additional un-
known pathway.
4.2 Tyk2 Associates with PI3-K in VSMC
PI3-K is central to cell migration processes regulated by cytokines and growth factors 
in diverse cell types including VSMC (Imai and Clemmons 1999). Moreover, PI3-K pos-
sesses a high capacity to cooperate with other signaling pathways to mediate a required 
functional response (Vanhaesebroeck and Waterfield 1999). Interestingly, several recent 
reports provide evidence for the interference of PI3-K and Jak/STAT signaling cascade. 
Thus, the PI3-K p85 regulatory subunit was shown to bind directly to STAT5 protein, which 
served as an adapter to couple the PI3-K signaling pathway to the interferon receptor in 
Daudi cells (Pfeffer et al., 1997). A similar interaction was demonstrated for the p85 sub-
unit and STAT5 protein in a bone marrow-derived Ba/F3 cell line, where both pathways 
cooperated to mediate interleukin-3-dependent suppression of apoptosis (Rosa Santos 
et al., 2000). Several other reports provided further evidence for coordinated activation of 
PI3-K and STAT proteins leading to the functional cooperation of both signaling cascades 
(Bao et al., 1999; Chen et al., 1999). Moreover, recent studies demonstrated the ability of 
Jaks to associate with and to regulate the p85 subunit of PI3-K, as was shown for Jak3 in 
human T cells (Sharfe et al., 1995), Jak1 in cardiac myocytes (Oh et al., 1998), and Jak2 
in human neutrophils (Al-Shami and Naccache 1999).
Consistent with these reports, we find that Janus kinase Tyk2, but not Jakl, Jak2, or 
Jak3, is specifically associated with PI3-K in human VSMC. Moreover, this association 
is uPA-dependent. The fact that Jak1 was not co-immunoprecipitated with PI3-K is of in-
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terest because in our previous studies we did not observe any difference between Tyk2 
and Jak1 in terms of uPA stimulation, uPAR association, and polarization to the leading 
edge of migrating cells (Dumler et al., 1998; Dumler et al., 1999). The inability to reveal 
Jak1-PI3-K complexes suggests that this kinase is most likely involved exclusively in the 
transcriptional regulation via STAT proteins or might perform an additional function in the 
uPA/uPAR-related signaling. Although we found no association between Jak1 and PI3-K, 
their cooperation cannot be completely excluded. Nevertheless, two kinases performing 
the same task would be redundant.
To address the molecular basis of Tyk2-PI3-K interaction, we performed an adenovi-
rus-mediated Tyk2 overexpression in VSMC. We performed Tyk2 pull-down assays using 
GST-p85 fusion proteins composed of either the C- or N-terminal SH2 domains of p85. 
Tyk2 bound to both N- and C-terminal SH2 domains of the p85 regulatory PI3-K subunit. 
This result is consistent with the findings of others demonstrating that these domains 
mediate specific protein-protein interactions (Vanhaesebroeck, Leevers et al. 1997). Tyk2 
has a candidate motif, YXXM, which is a potential site for p85 binding. However, determi-
nation of whether or not SH2 p85 domains are responsible for the interaction with Tyk2 
in the context of above motif requires further verification. Our data are the first to demon-
strate that following uPA stimulation, Tyk2 and PI3-K form a specific protein complex in 
VSMC. Although Tyk2 constitutively associates with p85, uPA induces a strong activation 
of this interaction. Moreover, uPA induces PI3-K activation within the complex, which we 
believe is mediated by tyrosine phosphorylation of the PI3-K p85 subunit. This hypothesis, 
which we are currently pursuing, is supported by the fact that growth factor-promoted p85 
phosphorylation increases PI3-K activity (Thakker et al., 1999). However, the increase 
in PI3-K activity we measured in Tyk2 precipitates in response to uPA was significantly 
less than the uPA-induced PI3-K activation in whole cell lysates. An intriguing question is 
raised by these observations, which imply additional still unknown uPA/uPAR-dependent 
PI3-K functions.
4.3 PI3-K in the Regulation of Cell Migration in Response to uPA
Our results highlight the importance of PI3-K in the regulation of cell migration in re-
sponse to uPA. We demonstrate the involvement of PI3-K in uPA-induced signaling lead-
ing to cell migration in two in vitro models, the Boyden chamber and the wounding assay. 
Both techniques allowed us to analyze different parameters of cell migration. Specific 
PI3-K antagonists, LY294002 and wortmannin, completely abrogated the uPA-responsive 
increase in cell motility. The observed ability of uPA to initiate sustained PI3-K activation 
might facilitate the long-term migration process. 
One of the issues raised by these observations is whether PI3-K lies upstream or 
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downstream of Tyk2 in the reavealed pathway. Our demonstration that in VSMC express-
ing the Tyk2 dominant negative form PI3-K activation in response to uPA is completely 
blocked implicates that PI3-K activation acts broadly downstream of Tyk2 in the signal 
transduction cascade. Moreover, these data support the concept that in VSMC Tyk2 is 
central to the PI3-K regulation. This positioning is further supported by our finding that a 
dominant negative Tyk2 blocks uPA-related cell migration. Upon stimulation, Tyk2, as cer-
tain other players in signaling machineries, relocates to the leading edge of the cell mem-
brane that might enhance reaction-limited signal transduction. The results of our study on 
VSMC morphology reported here imply that polarization of Tyk2 might contribute to the 
lamellipodial activity required for a spatial asymmetry of migrating cells. However, it ap-
pears that the loss of PI3-K activity has similar consequences on lamellipodial activity and 
migration process as blockage of Tyk2 by its mutant. Overall, these data favor the view 
that a functional relationship between two kinases is decisive for VSMC cytoskeletal re-
organization and migration. Our data are consistent with other reports demonstrating the 
central role of PI3-K in initiating actin cytoskeletal rearrangements, cell polarization, and 
cell migration in several cell systems (Hooshmand-Rad et al., 1997; Vicente-Manzanares 
et al., 1999). During these processes, PI3-K is generally translocated from the cytosol to 
the cytoskeleton-associated fraction presumably via a link to additional proteins (Meng 
and Lowell 1998). It is likely that Tyk2-PI3-K association via the SH2 domains of the p85 
subunit is responsible for bringing PI3-K to the cytoskeleton-associated subcellular frac-
tion, since loss of Tyk2 polarization in Ad5Tyk2KE-VSMC correlates with the loss of PI3-K 
activation and of leading edge formation. However, it is also possible that other adaptor 
molecules may facilitate translocation of PI3-K. In rat VSMC, Src kinase was presumed 
to cooperate functionally with uPAR and integrins at the leading edge upon the migration 
process, since uPA-caused a c-Src redistribution from the cytoplasm to plasma mem-
brane (Degryse et al., 1999). These data, coupled with the recent demonstration that the 
integrin-dependent cell migration requires both Src family kinases and PI3-K (Meng and 
Lowell 1998), as well as with our findings, suggest the existence of a complex functional 
unit formed at the leading cell membrane in response to uPA. The localized regulation of 
signaling molecules, such as Src, Tyk2, and PI3-K, by uPA/uPAR and integrins may pro-
vide an efficient mechanism for targeting downstream functional effects of these kinases 
as well as for the balance between these pathways.
4.4 Importance of uPA/uPAR System for VSMC Migration in a Coculture 
Model
In the last decade a great variety of animal studies were performed to establish a 
therapeutic strategy for the treatment of atherosclerosis and for prevention of restenosis 
after balloon angioplasty (Muller et al., 1992).  Despite several promising animal studies 
70
Discussion
showing a reduction of neointima formation after the administration of antiproliferative 
compounds, the transfer of these protocols to the human situation did not lead to a break-
through in restenosis therapy.  One of the main reasons responsible for this failure is the 
fact that the test models used are inadequate and do not allow a transfer to the human 
situation.  To overcome these obvious limitations, the alternative in vitro models might be 
very helpful to study communication between two or more cell types, which are neigh-
bored in the arterial vessel wall. After vascular injury, the endothelial integrity is disturbed 
and monocytes infiltrate into the injured vessels. The monocytes promote an inflamma-
tory response with generation of migratory and proliferative signals that converge on 
VSMC. The VSMC first migrate into the normally thin intimal layer and thereafter prolifer-
ate, causing neointimal formation and restenosis. The underlying molecular mechanisms 
remain, however, poorly defined. In this study, we have therefore established and used 
the coculture model with human VSMC and peripheral blood-derived monocytes that al-
lowed us to analyze the early cellular events in vascular remodeling. We show here that 
the uPA/uPAR system is upregulated upon VSMC-monocyte interaction and serves as a 
promigratory signal thus contributing to increased VSMC motility.
The uPA/uPAR system is known to be involved in tissue remodeling and wound healing 
by affecting cell adhesion, migration, and proliferation (Ossowski and Aguirre-Ghiso, 2000). 
It has been also demonstrated in different in vitro models that uPA induces accelerated migra-
tion of VSMC (Noda-Heiny and Sobel, 1995; Degryse et al., 1999; Kusch et al., 2000; Mukhina 
et al., 2000). By time-lapse video microscopy performed directly on the cocultures, we ob-
served, surprisingly, that changes in VSMC migration due to coculture were equivalent to the 
maximal effect achieved in VSMC monoculture stimulated with uPA (Fig.  27). Moreover, the 
increase in cell motility determined by either uPA or monocytes was completely abolished 
after addition to mono- and coculture of the soluble uPAR (suPAR) as a competitor for the uPA 
binding (Fig. 27). These data suggest that the increased VSMC migration in coculture might 
be induced by an upregulated expression of uPA. To verify this hypothesis, we measured the 
amount of uPA secreted upon coculture in cell-free fractions. The results of the quantitative 
ELISA shown in Fig. 24A demonstrate a five-fold increase of uPA production during coculture. 
Interestingly, the maximal uPA secretion was reached on day three of coculture, whereas the 
pronounced changes in cell adhesion and migration were observed already on day two (Fig. 
24 ). One possible explanation for this discrepancy might be the increased expression of the 
cell surface uPAR, as detected by flow cytometry in VSMC on day two (Fig.  24). As uPAR 
provides high affinity binding sites for uPA, this increase would amplify uPA-dependent migra-
tory signals. The expression of uPAR on monocytes was not changed upon coculture (data not 
shown). To determine the source of the increased uPA expression in coculture, RT-PCR was 
performed separately in cocul-tured VSMC and in monocytes. As shown in Fig.  24 cocul-
tured monocytes display strong upregulation of uPA expression, whereas cocultured VSMC 
revealed no quantitative differences of uPA expression (data not shown). The results of RT-
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PCR analysis of uPAR expression in VSMC (Fig.  24) are consistent with the data discussed 
above obtained by flow cytometry (Fig.  24 ). Thus, uPAR is highly expressed in VSMC cocul-
tured with monocytes, whereas its expression in monocytes does not change.
Taken together, our findings indicate that coculture of human VSMC and peripheral blood-
derived monocytes leads to the increase of VSMC motility through a mechanism(s) involv-
ing increased expression of uPA by monocytes and of cell-surface uPAR by VSMC. These 
findings might have important implications for several vascular diseases, such as restenosis 
and arteriosclerosis involving infiltration of inflammatory cells followed by VSMC migration 
at sites of vascular injury. This study supports and extends the usefulness of the in vitro 
coculture model, which overcomes the obvious limitations of animal models and allows to 
study the communication between two interacting cell types (Axel et al., 1997; Bhatia et al., 
1999; Streblow et al., 1999). Using this experimental system, we found that monocytes were 
able to affect VSMC function by either direct contact or transfilter coculture. The fact that 
a direct interaction was not mandatory suggests that the monocyte-interacting cells might 
specify the regulatory effects of monocytes. It has been recently demonstrated that both 
peripheral blood cells and endothelial cells can release su-PAR, and that this release was 
enhanced when either mononuclear cells or thrombocytes were cultured together with en-
dothelial cells (Mustjoki et al., 2000). In this case, however, coculture without cell contact failed 
to enhance suPAR release. Although uPA is a well-documented migratory signal for VSMC, 
most biological activities of uPA have been studied using exogenous recombinant or purified 
protein or peptides (Fazioli et al., 1997; Degryse et al., 1999; Kusch et al., 2000; Mukhina 
et al., 2000). Our study is the first to demonstrate the net effect of the monocyte-secreted 
endogenous uPA on VSMC migration. The effects observed in our coculture model might 
have a counterpart in vivo during the early phase of monocyte entry into the arterial wall under 
pathological conditions.
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